

(19)



(11)

EP 0 762 903 B2

(12)

NEW EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the opposition decision:
22.08.2007 Bulletin 2007/34

(45) Mention of the grant of the patent:
17.09.2003 Bulletin 2003/38

(21) Application number: **95922126.8**

(22) Date of filing: **02.06.1995**

(51) Int Cl.:
A61L 27/00 (2006.01)

(86) International application number:
PCT/US1995/006724

(87) International publication number:
WO 1995/033502 (14.12.1995 Gazette 1995/53)

(54) **MANUFACTURE OF AUTOGENOUS REPLACEMENT BODY PARTS**

HERSTLLUNG VON AUTOGENEN KÖRPERERSATZTEILEN

RECONSTITUTION AUTOGENE D'ELEMENTS DU CORPS

(84) Designated Contracting States:
**AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL
PT SE**

(30) Priority: **03.06.1994 US 253398**

(43) Date of publication of application:
19.03.1997 Bulletin 1997/12

(73) Proprietor: **STRYKER CORPORATION**
Kalamazoo, MI 49001 (US)

(72) Inventors:
• **KHOURI, Roger, K.**
St. Louis, MO 63112 (US)
• **SAMPATH, Kuber, T.**
Medway, MA 02053 (US)
• **RUEGER, David, C.**
Southborough, Massachusetts 01772 (US)

(74) Representative: **Hutchins, Michael Richard et al**
FRY HEATH & SPENCE LLP
The Gables
Massetts Road
Horley
Surrey RH6 7DQ (GB)

(56) References cited:

EP-A- 0 206 801	EP-A- 0 522 569
EP-A- 0 567 391	WO-A-02/43759
WO-A-88/00205	WO-A-89/09788
WO-A-90/11366	WO-A-91/05802
WO-A-91/18558	WO-A-92/15323
WO-A-93/09229	WO-A-93/25246
WO-A-94/26892	WO-A-95/16035
US-A- 5 011 691	US-A- 5 166 058
US-A- 5 635 373	US-A- 5 849 880
US-B- 6 764 994	

- Internet Publication "Collagen Table", pp. 1-3
- Seeherman et al., 2002, Sine, vol. 27(16S):16-23
- Peng et al., 2003, J. Cell. Biochem., 90:1149-1165
- Nature, 1987, 325:81-84

EP 0 762 903 B2

DescriptionField of the Invention

5 **[0001]** This invention relates to materials and uses of such materials for the repair and regeneration of plural distinct tissues at a single defect site in a mammal. More particularly, the invention is concerned with materials and uses of such materials for the manufacture in vivo of autogenous replacement body parts, including mammalian skeletal joints, comprising plural different tissues, such as ligament, articular cartilage and bone tissues.

Background of the Invention

10 **[0002]** Skeletal joints provide a movable union of two or more bones. Synovial joints are highly evolved articulating joints that permit free movement. Because mammalian lower limbs are concerned with locomotion and upper limbs provide versatility of movement, most of the joints in the extremities are of the synovial type. There are various types of synovial joints. Their classification is based upon the types of active motion that they permit (uniaxial, biaxial, and polyaxial). They are differentiated further according to their principal morphological features (hinge, pivot, condyloid). In contrast to fibrous and cartilaginous joints where the ends of the bones are found in continuity with intervening tissue, the ends of the bones in a synovial joint are in contact, but separate. Because the bones are not bound internally, the integrity of a synovial joint results from its ligaments and capsule (which bind the articulation externally) and to some extent from the surrounding muscles. In synovial joints, the contiguous bony surfaces are covered with articular or, hyaline cartilage, and the joint cavity is surrounded by a fibrous capsule which segregates the joint from the surrounding vascularized environment. The inner surface of the capsule is lined by a synovial layer or "membrane" containing cells involved in secreting the viscous lubricating synovial fluid. Gray, Anatomy of the Human Body, pp. 312; 333-336 (13th ed.; C.C. Clemente, ed., (1985)).

25 **[0003]** In certain synovial joints, the joint or synovial cavity may be divided by a meniscus of fibrocartilage. Synovial joints involving two bones and containing a single joint cavity are referred to as simple joints. Joints that contain a meniscus forming two joint cavities are called composite joints. The term compound joint is used for those articulations in which more than a single pair of articulating surfaces are present.

30 **[0004]** Joint replacement, particularly articulating joint replacement, is a commonly performed procedure in orthopedic surgery. However, the ideal material for replacement joints remains elusive. Typically, joint reconstruction requires repair of the bony defect, the articular cartilage and, in addition, one or more of the joining ligaments. To date, there are no satisfactory clinical means for readily repairing both articular cartilage and bony defects within a joint which reliably results in viable, fully-functional weight-bearing joints. Prosthetic joints which replace all the endogenous joint tissues circumvent some of these problems. However, prosthetic joints have numerous, well documented limitations, particularly in younger and highly active patients. In addition, in some circumstances prosthetic joint replacement is not possible and repair options are limited to osteochondroallograft materials.

35 **[0005]** The articular, or hyaline cartilage, found at the end of articulating bones is a specialized, histologically distinct tissue and is responsible for the distribution of load resistance to compressive forces, and the smooth gliding that is part of joint function. Articular cartilage has little or no self-regenerative properties. Thus, if the articular cartilage is torn or worn down in thickness or is otherwise damaged as a function of time, disease or trauma, its ability to protect the underlying bone surface is compromised.

40 **[0006]** Other types of cartilage in skeletal joints include fibrocartilage and elastic cartilage. Secondary cartilaginous joints are formed by discs of fibrocartilage which join vertebrae in the vertebral column. In fibrocartilage, the mucopolysaccharide network is interlaced with prominent collagen bundles and the chondrocytes are more widely scattered than in hyaline cartilage. Elastic cartilage contains collagen fibers which are histologically similar to elastin fibers. As with other connective tissues the formation of cartilaginous tissue is a complex biological process, involving the interaction of cells and collagen fibers in a unique biochemical milieu.

45 **[0007]** Cartilage tissue, including articular cartilage, unlike other connective tissues, lacks blood vessels, nerves, lymphatics and basement membrane. Cartilage is composed of chondrocytes which synthesize an abundant extracellular milieu composed of water, collagens, proteoglycans and noncollagenous proteins and lipids. Collagen serves to trap proteoglycans and to provide tensile strength to the tissue. Type II collagen is the predominant collagen in cartilage tissue. The proteoglycans are composed of a variable number of glycosaminoglycan chains, keratin sulphate, chondroitin sulphate and/or dermatan sulphate, and N-linked and O-linked oligosaccharides covalently bound to a protein core. The sulfated glycosaminoglycans are negatively charged resulting in an osmotic swelling pressure that draws in water.

50 **[0008]** In contrast, certain collagens such as the fibrotic cartilaginous tissues which occur in scar tissue for example, are keloid and typical of scar-type tissue, i.e., composed of capillaries and abundant, irregular, disorganized bundles of Type I and Type II collagen.

55 **[0009]** Histologically, articular or hyaline cartilage can be distinguished from other forms of cartilage, both by its

Cart.

medium itself or of bone tissue per se. Moreover, relative to cartilage tissue, the collagen present in bone tissue exists in a highly-organized parallel arrangement.

[0018] Bony defects, whether from degenerative, traumatic or cancerous etiologies, pose a formidable challenge to the reconstructive surgeon. Particularly difficult is reconstruction or repair of skeletal parts that comprise part of a multi-tissue complex, such as occurs in mammalian joints.

[0019] Mammalian bone tissue is known to contain one or more proteinaceous materials presumably active during growth and natural bone healing which can induce a developmental cascade of cellular events resulting in endochondral bone formation. The developmental cascade involved in endochondral bone differentiation consists of chemotaxis of mesenchymal cells, proliferation of progenitor cells into chondrocytes and osteoblasts, differentiation of cartilage, vascular invasion, bone formation, remodeling, and finally marrow differentiation.

[0020] True osteogenic factors capable of inducing the above-described cascade of events that result in endochondral bone formation have now been identified, isolated, and cloned. These proteins, which occur in nature as disulfide-bonded dimeric proteins, are referred to in the art as "osteogenic" proteins, "osteoinductive" proteins, and "bone morphogenetic" proteins. Whether naturally-occurring or synthetically prepared, these osteogenic proteins, when implanted in a mammal typically in association with a substrate that allows the attachment, proliferation and differentiation of migratory progenitor cells, are capable of inducing recruitment of accessible progenitor cells and stimulating their proliferation, inducing differentiation into chondrocytes and osteoblasts, and further inducing differentiation of intermediate cartilage, vascularization, bone formation, remodeling, and finally marrow differentiation. Those proteins are referred to as members of the Vgr-1/OP1 protein subfamily of the TGP β super gene family of structurally related proteins. Members include the proteins described in the art as OP1 (BMP-7), OP2 (BMP-8), BMP2, BMP3, BMP4, BMP5, BMP6, 60A, DPP, Vgr-1 and Vgl. See, e.g., U.S. 5,011,691; U.S. 5,266,683, Ozkaynak et al. (1990) EMBO J. 9: 2085-2093, Wharton et al. (1991) PNAS 88:9214-9218, (Ozkaynak (1992) J. Biol. Chem. 267:25220-25227 and U.S. 5,266,683); (Celeste et al. (1990) PNAS 87:9843-9847); (Lyons et al. (1989) PNAS 86:4554-4558). These disclosures describe the amino acid and DNA sequences, as well as the chemical and physical characteristics of these proteins. See also (Wozney et al. (1988) Science 242:1528-1533); BMP 9 (WO93/00432, published January 7, 1993); DPP (Padgett et al. (1987) Nature 325: 81-84; and Vg-1 (Weeks (1987) Cell 51:861-867).

[0021] It is an object of the instant invention to provide a bioresorbable matrix and device, suitable for regenerating body parts which comprise two or more functionally- and structurally-associated yet distinct replacement tissues in a mammal. Another object is to provide compositions and uses of such compositions for the repair or complete reconstruction of a mechanically and functionally viable skeletal joint in a mammal, particularly an articulating or synovial joint, as well as other body parts comprising bone and bona fide hyaline cartilage, without relying on prosthetic devices. Another object is to provide materials and uses of such materials for the repair of tissue defects in an articulating mammalian joint, so as to form a mechanically and functionally viable joint comprising bone and articular cartilage, ligament, tendon, synovial membrane and synovial capsule tissue. Another object of the invention is to provide means for restoring functional non-mineralized tissue in a skeletal joint including the avascular tissue therein.

Summary of the Invention

[0022] In accordance with the present invention, devices are provided as claimed in claim 1. In one aspect the replacement body part includes part or all of a mammalian skeletal joint, including an articulating or synovial joint. As described herein below, the compositions of the invention are sufficient to restore mechanical and functional viability of the tissues associated with a skeletal joint, including bone (and bone marrow), articular cartilage, ligament, tendon, synovial capsule and synovial membrane tissues. Thus the invention provides and uses of such compositions for replacement of one or more of the plural distinct tissues that define a mammalian skeletal joint.

[0023] The invention provides, in one aspect therefore, a device as claimed in claim 1. The matrix comprises residues derived from at least two distinct tissues of the replacement body part. As will be appreciated from the description provided herein below, the matrix can include residues specific for four or more distinct tissues. The matrix is biocompatible and bioresorbable. Specifically, it is sufficiently free of pathogens and antigenic stimuli that can result in graft rejection. Preferably the matrix is derived from an allogenic or xenogenic body part. Preferably, it is derived from a mammalian donor, such as a cadaver. The body part may be rendered inert or "devitalized" by dehydration, such as by ethanol extraction and lyophilization, so that no residual cellular metabolism remains, but the function of endogenous growth factors and the like can be restored upon in situ reconstitution by endogenous body fluids. The treated body part which now is substantially depleted in antigenic and pathogenic components and now is biocompatible, maintains the residues specific for the plural distinct tissues constituting the body part sought to be replaced. These residues include those of plural distinct tissues with dimensions and structural relationships to each other which mimic those of the body part to be replaced.

[0024] The thus treated matrix having utility in the devices of the invention lacks significant mechanical integrity as compared with native tissue and, on its own, is not sufficient to induce regeneration of a replacement body part or tissue

when implanted. However, by impregnating or otherwise infusing the interstices of the matrix with osteogenic protein so that the protein is disposed on or adsorbed to, the surfaces of the matrix, the device of the instant invention is formed and is sufficient to induce formation of new tissue in vivo such that regeneration of a mechanically and functionally viable replacement body part occurs in situ.

5 [0025] In one preferred embodiment, the device comprises part or all of a skeletal joint excised from a mammalian donor allogenic or xenogenic to the donee. Treated as described herein the device comprising the allogenic or xenogenic skeletal joint (1) is biocompatible, namely, it is non-pathogenic and sufficiently non-antigenic to prevent graft rejection in vivo, and (2) is sufficient to induce formation of a functionally viable autogenous replacement joint in vivo, including generating functional bone, articular cartilage, ligament and capsule tissue in correct relation to one another such that

10 [0026] In another embodiment, the invention provides a device suitable for serving as a template for forming in vivo a functional skeletal joint or part thereof, as claimed in claim 1. The newly formed tissues assume the shape and function of the original tissue in the skeletal joint.

15 [0027] In another aspect, the invention provides uses as claimed claims 3 to 5 and 7, 7-10, 13-14, 16-18, 20-22, 24-29 + 46-51 of the matrix and osteogenic protein of claim 1 for the manufacture of the device described above. In one embodiment, such a use also comprises providing a supply of mesenchymal cells to the implanted device, as by threading or otherwise providing a muscle flap perfused with a blood supply into a hollow portion of the device. In another embodiment, the device is implanted at a locus in the body of the individual distinct from the defect site but which allows generation of the replacement body part. The autogenous body part thus formed then can be implanted at the defect site.

20 [0028] As will be appreciated from the description provided herein that the invention finds application in the functional and mechanical restoration of one or more individual tissues in a mammalian skeletal joint, including the non-mineralized and avascular tissue therein. Thus, in one embodiment, the invention provides devices competent for restoring, without limitation, functional articular cartilage, ligament, synovial membrane and synovial capsule tissue. The devices described herein can be used for example, to correct superficial articular cartilage defects in a joint, to replace form or compromised ligaments and/or tendons, and to repair defects in synovial capsule or membrane tissue.

25 [0029] The devices for repairing individual skeletal joint tissue comprise osteogenic protein disposed on a matrix containing residues derived from plural distinct tissues of a skeletal joint, including, without limitation, cartilage, ligament, tendon, synovial capsule, or synovial membrane tissue. Preferably, the matrix is derived from allogenic or xenogenic tissue, and is treated as described herein to form a biocompatible devitalized matrix.

30 [0030] When used in accordance with the uses of the instant invention, the devices of the invention and/or the tissues which result from their application, essentially satisfy the following criteria of a preferred grafting material:

1. They result in formation of mechanically and functionally viable tissues normally present at the site. These tissues are of an appropriate size and have correct structural relationships so as to result in a functional body part in particular, the multi-tissue replacement part, whether produced in situ at the site of intended use or remotely, becomes incorporated, integrating with adjacent tissues, essentially maintaining its shape, and avoiding abnormal resorption, regardless of the conditions present at the recipient site. Welland et al. (1983) Clin. Orthop. 174:87 (1983).
2. The devices are capable of being precisely contoured and shaped to exactly match any defect, whichever complex skeletal or organ shape it is meant to replace.
3. The devices virtually have unlimited supply and are relatively easy to obtain.
4. The devices have minimal donor site morbidity.

35 [0031] Furthermore, the instant invention provides practitioners with materials and use of such materials for skeletal joint repair including the repair of the bone and articular cartilage present therein, and which solve problems that occur using the methods and devices of the art. For example, the instant invention can induce formation of bona fide hyaline cartilage rather than fibrocartilage at a defect site. Using the materials and methods disclosed herein, functional hyaline cartilage forms on the articulating surface of bone at a defect site and does not degenerate over time to fibrocartilage. By contrast, prior art methods of repairing cartilage defects generally result in development of fibrous cartilage at the defect site. Unlike hyaline cartilage, fibrocartilage lacks the physiological ability to restore articulating joints to their full capacity. Thus, when the instant materials are used in accordance with the instant methods, the practitioner can substantially functionally restore a cartilage defect in an articulating joint, particularly a superficial articular cartilage defect and substantially avoid the undesirable formation of fibrocartilage typical of prior art methods, or degeneration into a "full-thickness defect". The invention also provides means for repairing individual tissue of a joint not readily reparable individually using prior art methods, and which, in some cases, previously warranted replacement of the entire joint with a prosthetic device. The invention further allows use of allogenic replacement materials for repairing the avascular tissue in a skeletal joint, and which result in the formation of mechanically and functionally viable replacement tissues at a joint locus.

Brief Description of the Drawings

[0032] While the specification concludes with claims particularly pointing out and specifically claiming the subject matter which is regarded as constituting the present invention, it is believed that the invention will be better understood from the following detailed description of preferred embodiments taken in conjunction with the accompanying drawings in which:

Fig. 1 is a fragmentary front elevational view of a mammalian knee joint with sufficient tissue removed to show the articular cartilage on the condyles of the femur, the ligaments, synovial membrane, joint capsule, and further showing a damaged area in the articular cartilage requiring repair

FIGS. 2A through 2D are schematic representations of the elements used to generate a viable functional glenohumoral hemi-joint in one embodiment of the invention. Fig. 2A depicts a lyophilized allograft; Fig. 2B depicts osteogenic protein for application to the lyophilized allograft of Fig. 2A; Fig. 2C depicts a muscle flap of cutaneous maximus muscle to be threaded inside the shaft of the lyophilized allograft; and, Fig. 2D depicts a viable, functional hemi-joint resulting from the combination of elements in Figs. 2A, 2B and 2C. Fig. 2D represents one embodiment of the device of the instant invention;

FIGS. 3A through 3D are schematic representations of the four allografts tested in the hemi-joint of Example 2 (5 week); and

FIGS. 4A through 4D are schematic representations of the four allografts tested in the hemi-joint of Example 3- (6 month).

Detailed Description

[0033] Described herein are novel materials and uses provided for the repair and regeneration of plural distinct tissues of a skeletal joint. The replacement body part is a skeletal joint, particularly an articulating joint, and includes, without limitation, residues or derived from, bone; cartilage ligament, tendon, synovial capsule and synovial membrane tissue.

[0034] More particularly, in one aspect, the invention provides a device as claimed in claim 1. As used herein, the term "matrix" is understood to define a structure having interstices for the attachment, proliferation and differentiation of infiltrating cells. It comprises residues derived from the tissue to be replaced and has a shape and dimension when implanted which substantially mimics that of the replacement tissue desired.

[0035] As used herein, the term "residue" is intended to mean a constituent of a given tissue, which is derived from the non-viable constituents of the given tissue. A matrix comprising these residue(s), when combined with osteogenic protein, and implanted in a mammal in an environment which mimics the tissue's local environment under physiological conditions, and is sufficient for formation of specific, mechanically and functionally viable replacement tissue.

[0036] The term "plural distinct tissue" is intended to mean physiologically distinguishable tissues, such as biochemically or ultrastructurally distinguishable tissues which reside at an anatomically similar locus. In an articulating replacement joint device for example, the matrix can comprise residues derived from, bone, cartilage, ligament, tendon and synovial membrane tissue. Thus, a significant aspect of the matrix of the invention is a single structure comprising residues of plural, distinct tissues, and which, when combined with an osteogenic protein as defined herein, is suitable for inducing repair or regeneration of a body part that is mechanically and functionally viable over time *in vivo*.

[0037] As used herein, the terms "bone" and "articular cartilage" are intended to mean the following: Bone refers to a calcified (mineralized) connective tissue primarily comprising a composite of deposited calcium and phosphate in the form of hydroxyapatite, collagen (predominantly Type I collagen) and bone cells, such as osteoblasts, osteocytes and osteoclasts, as well as to the bone marrow tissue which forms in the interior of true endochondral bone. Cartilage refers to a type of connective tissue that contains chondrocytes embedded in an extracellular network comprising fibrils of collagen (predominantly Type II collagen along with other minor types, e.g. Types IX and XI), various proteoglycans (e.g., chondroitin sulfate, keratan sulfate, and dermatan sulfate proteoglycans), other proteins, and water. Articular cartilage refers to hyaline or articular cartilage, an avascular, non-mineralized tissue which covers the articulating surfaces of the portions of bones in joints and allows movement in joints without direct bone-to-bone contact and thereby prevents wearing down and damage to opposing bone surfaces. Most normal healthy articular cartilage is referred to as "hyaline," i.e., having a characteristic frosted glass appearance. Under physiological conditions, articular cartilage tissue tests on the underlying, mineralized bone surface: the subchondral bone, which contains highly vascularized ossicles. These highly vascularized ossicles can provide diffusible nutrients to the overlying cartilage, but not mesenchymal stem cells.

[0038] "Ligament" is intended to mean both the rope-like structures of white fibrous connective tissue which attach anterior extremities of interacting bones, as well as the tissue defining a synovial capsule. "Synovial membrane" is intended

CAR
1

to define the connective tissue membrane lining the interior of the synovial cavity and which is involved in synovial fluid secretion. "Tendon" is intended to define the connective tissue Structure which joins muscle to bone.

Replacement Body Parts

[0039] As disclosed herein, the instant invention provide uses and compositions for replacing and repairing a defective body part. The uses inverting surgically excising the defective body part, implanting a device comprising a matrix of the type described above at the site of excision, and as necessary, surgically repairing tissues adjacent the site of excision as described herein below. For example, for synovial joint replacement, it is desirable to repair the joint capsule, including the synovial membrane and ligaments, so as to surgically approximate the joint structure as it occurs physiological conditions, thereby recreating the avascular environment which is the synovial cavity and which is bathed in synovial fluid. It also is preferable to suture or otherwise mechanically temporarily connect the implanted device to surrounding tissue.

[0040] In one embodiment the device is constructed to replace part or all of a mammalian skeletal joint structure and includes a matrix having residues derived from plural, distinct tissues, including two or more of bone, cartilage, ligament, tendon, synovial capsule and/or synovial membrane tissue. The matrix comprises devitalized non-mineralized tissue. In a preferred embodiment, the replacement tissue can include articular cartilage, ligament, bone, tendon or synovial capsule tissue.

[0041] In a partial or complete joint replacement, it is preferred but not required to include in the practice of the method the additional step of threading a muscle flap into a hollow portion of the implanted device. For example, using the method described in Khouri, U.S. 5,067,963, and herewith below, a muscle flap, which can itself be pretreated with osteogenic protein, can be surgically introduced into a cavity in the implanted matrix, such as the marrow cavity of devitalized bone, to provide a blood supply to expedite morphogenesis of vascularized tissue and to provide a ready supply of mesenchymal stem cells.

[0042] The matrix of instant invention has utility as an implantable device when osteogenic protein is disposed on the surfaces of the matrix, present in an amount sufficient to induce formation of each of the replacement tissues. This permits regeneration of the body part within the mammal, including plural tissues of appropriate size, interrelationship, and function. Osteogenic proteins contemplated to be useful in the instant invention are described below and have been earlier-described in, for example, U.S. Pat. Nos. 4,968,590, 5,258,499 and 5,266,683. The osteogenic protein can be, for example, any of the known bone morphogenetic proteins and/or equivalents thereof described herein and/or in the art and includes naturally sourced material, recombinant material, and any material otherwise produced which is capable of inducing tissue morphogenesis.

[0043] The uses and materials of the instant invention are especially useful for the repair and/or partial or complete replacement of mammalian body joints, including, without limitation, articulating joints, particularly joints enclosed by a ligamentous capsule and bathed in synovial fluid.

[0044] In some synovial joints, the movement is uniaxial, i.e., all movements take place around one axis: Among these are the ginglymus or hinge joint in which the axis of movement is transverse to the axes of the bones, and the trochoid or pivot joint in which the axis is longitudinal. In the case of biaxial synovial joints, movements are around two axes at a right angle or any other angle to each other: These include the condyloid, the ellipsoid, and the saddle joints. There is a third type of synovial joint, the spheroidal or ball-and-socket joint, in which the movements are polyaxial, i.e., movements are permitted in an infinite number of axes. Finally, there are the plane or gliding-type synovial joints.

[0045] In hinge joints, the articular surfaces are molded to each other in such a manner as to permit motion in only one plane around the transverse axis. Flexion at the elbow joint is an example; other examples include the interphalangeal joints of both the fingers and toes. In pivot joints, movement in a pivot joint also occurs around a single axis, however, it is the longitudinal axis. There are several pivot joints in the human body, such as the proximal radioulnar articulation. In condylar joints include, movement occurs principally in one plane. The tibiofemoral articulation of the knee joint is an example. In ellipsoid joint include, movement is around two principal axes which are at right angles to each other. Examples of these joints include the radiocarpal and metacarpophalangeal joints. In a saddle joint, the articular end of the proximal bone is concave in one axis and convex in a perpendicular axis. These surfaces fit reciprocally into convex and concave surfaces of the distal bone. The best example of a saddle joint is the carpometacarpal joint of the thumb. A ball-and-socket joint is one in which the distal bone is capable of motion around an indefinite number of axes with one common center. Examples of this form of articulation are found in the hip and shoulder joints. A plane or gliding-type joint allows a slight slipping or sliding of one bone over the other. Unlike the above-described joints, the amount of motion between the surfaces is limited by the ligaments or osseous processes that surround the articulation. This is the form present in the joints between the articular processes of certain vertebrae, the carpal joints, and the intermetatarsal joints.

[0046] Although it is contemplated that the present invention is usable to repair defects including bone and articular cartilage elsewhere in a mammalian body, aspects of the invention are here illustrated in connection with the articulating surfaces on the femur in a knee joint 10 illustrated in FIG. 1.

[0047] FIG. 1 illustrates a knee joint 10 between the bottom of a femur 11 and the top of a tibia 12. For clarity of illustration, only portions 13 and 14 of the medial and lateral collateral ligaments which movably tie the femur 11 to the underlying tibia 12 and fibula 15, are shown in FIG. 1. Similarly, the joint capsule is represented by the exterior dark lining 25, and the synovial membrane, which lines the synovial cavity and secretes the lubricating synovial fluid is represented by the interior dark lining 26. Normally interposed between the opposing surfaces of the femur 11 and tibia 12 are lateral and medial meniscus cartilages 16 and 17 and anterior and posterior cruciate ligaments (not shown). The convexly curved condyles 20 and 21 at the lower end of the femur 11 are normally supported by the meniscus cartilages 16 and 17, respectively, on the upper end of the tibia 12. Normally, the lower end of the femur 11, including the condyles 20 and 21, are covered by a layer 22 of hyaline cartilage material, referred to as the articular cartilage 22. The articular cartilage 22 forms a generally resilient padding which is fixed on the surface of the lower end of the femur 11 to protect the latter from wear and mechanical shock. Moreover, the articular cartilage 22, when lubricated by the synovial fluid in the knee joint 10, provides a surface which is readily slidable on the underlying surfaces of the meniscus cartilages 16 and 17 (or on the upper surface of the tibia 12 should one or both of the meniscus cartilage 16 and 17 be partly or totally absent) during articulation of the knee joint 10.

[0048] A portion of the articular cartilage may become damaged by injury or disease, or become excessively worn. FIG. 1 illustrates an example of a damaged area 23.

Matrix Considerations

[0049] In the instant invention, the substrate serves as a scaffold upon which certain cellular events, mediated by an osteogenic protein, necessarily will occur. The specific responses to the osteogenic protein ultimately are dictated by the endogenous microenvironment at the implant site and the developmental potential of the responding cells. As also will be appreciated by the skilled artisan, the precise choice of substrate utilized for the matrices disclosed herein will depend, in part, upon the type of defect to be repaired, anatomical considerations such as the extent of vascularization at the defect site, and the like.

[0050] The matrix of the invention may be obtained as follows. A replacement tissue or body part to be used as a replacement body part and which comprises at least two distinct tissues in association to form the body part, is provided, as from a cadaver, or from a bone bank and treated, as by ethanol treatment and dehydrated by lyophilization, so that the remaining material is non-pathogenic and sufficient non-antigenic to prevent graft rejection. As described above, the thus treated material having utility in the devices of the invention further comprises the residues of the extracted tissue or tissues from which it is derived. A replacement body part matrix thus treated further is dimensioned such that the residues have a structural relationship to each other which mimic that of the body part to be replaced.

Natural-sourced Matrices

[0051] Suitable allogenic or xenogenic matrices can be created as described herein below, using methods well known in the art. Preferably, the replacement body part or tissue is obtained fresh, from a cadaver or from a tissue bank which freezes its tissues upon harvest. In all cases and as will be appreciated by the practitioner in the field, it is preferable to freeze any tissue upon harvest, unless the tissue is to be put to immediate use. Prior to use, the tissue is treated with a suitable agent to extract the cellular non-structural components of the tissue so as to devitalize the tissue. The agent also should be capable of extracting any growth inhibiting components associated with the tissue, as well as to extract or otherwise destroy any pathogens. The resulting material is an acellular matrix defining interstices that can be infiltrated by cells, and is substantially depleted in non-structurally-associated components.

[0052] In a currently preferred procedure, the tissue is devitalized following a methodology such as that used in the art for fixing tissue. The tissue is exposed to a non-polar solvent, such as 100% (200 proof) ethanol, for a time sufficient to substantially replace the water content of the tissue with ethanol and to destroy the cellular structure of the tissue. Typically, the tissue is exposed to 200 proof ethanol for several days, at a temperature in the range of about 4° - 40°C, taking care to replace the solution with fresh ethanol every 6-12 hours, until such time as the liquid content of the tissue comprises 70-90% ethanol. Typically, treatment for 3-4 days is appropriate. The volume of liquid added should be more than enough to submerge the tissue. The treated tissue then is lyophilized. The resulting, dry matrix is substantially depleted in non-structural components but retains both intracellular and extracellular matrix components derived from the tissue.

[0053] Numerous other methods are described in the art for extracting tissues, including mineralized tissue such as bone, and for rendering these tissues biocompatible for allogenic or xenogenic implants. See, for example, Sampath et al. (1983) PNAS 80:6591-6595, US 5,011,691, and U.S. Patent Nos. 4,975,526 and 5,171,574. These publications describe extraction with 4M guanidine-HCl, 50mM Tris-HCl, pH 7.0 for 16 hours at 4°C, and various deglycosylating and collagen fibril modifying agents, including hydrogen fluoride, trifluoroacetic acid, dichloromethane, acetonitrile, isopropanol, heated, acidic aqueous solutions, and various combinations of these reagents. The disclosures of the patents is

incorporated herein by reference. As described therein and below, where the matrix is treated with a fibril-modifying agent, the treated matrix can be washed to remove any extracted components, following a form of the procedure set forth below:

1. Suspend matrix preparation in TBS (Tris-buffered saline) 1g/200 ml and stir at 4°C for 2 hrs; or in 6 M urea. 50 mM Tris-HCl. 500 mM NaCl, pH 7.0 (UTBS) or water and stir at room temperature (RT) for 30 minutes (sufficient time to neutralize the pH);
2. Centrifuge and repeat wash step; and
3. Centrifuge; discard supernatant; water wash residue; and then lyophilize.

[0054] Treated allogenic or xenogenic matrices are envisioned to have particular utility for creating devices for forming replacement body parts comprising plural distinct tissues, as well as for creating devices for replacing individual joint tissues, such as ligament and articular cartilage tissue. For example, a replacement ligament device can be formulated from an allogenic ligament matrix and osteogenic protein, and implanted at a skeletal joint locus following standard surgical procedures for autogenous ligament replacement. Similarly, an allogenic articular cartilage device can be formed from devitalized cartilage tissue, or other inert, non-mineralized matrix material and osteogenic protein, and the device laid on the subchondral bone surface as a sheet. Alternatively, a formulated device can be pulverized or otherwise mechanically abraded to produce particles which can be formulated into a paste or gel as described herein for application to the bone surface.

Formulation Considerations

[0055] The devices of the invention can be formulated using any of the methods described in the art for formulating osteogenic devices. See, for example, US Patent No. 5,266,683. Briefly, osteogenic protein typically is dissolved in a suitable solvent and combined with the matrix. The components are allowed to associate. Typically, the combined material then is lyophilized, with the result that the osteogenic protein is disposed on, or adsorbed to the surfaces of the matrix. Useful solubilizing solvents include, without limitation, an ethanoltrifluoroacetic acid solution, e.g., 47.5% EtOH/0.01% TFA; and acetonitrile/TFA solution, ethanol or ethanol in water, and physiologically buffered saline solutions. Formulations in an acidic buffer can facilitate adsorption of OP1 onto the matrix surface. For the replacement body part devices of the invention, the currently preferred formulation protocol is incubation of matrix and osteogenic protein in an ethanol/TFA solution (e.g., 30-40% EtOH/0.01-0.1%TFA) for 24 hours, followed by lyophilization. This procedure is sufficient to adsorb or precipitate 70-90% of the protein onto the matrix surface.

[0056] The quantity of osteogenic protein used will depend on the size of replacement device to be used and on the specific activity of the osteogenic protein. Typically, 0.5 mg-100 mg/10 g of matrix, dry weight, can be used to advantage.

[0057] In addition to osteogenic proteins, various growth factors, hormones, enzymes, therapeutic compositions, antibiotics, or other bioactive agents also can be adsorbed onto, or impregnated within, a substrate and released over time when implanted and the matrix slowly is absorbed. Thus, various known growth factors such as EGF, PDGF, IGF, FGF, TGF- α , and TGF- β can be released in vivo. The matrix can also be used to release chemotherapeutic agents, insulin, enzymes, enzyme inhibitors or chemotactic-chemoattractant factors.

Protein Considerations

[0058] As defined herein, the osteogenic proteins useful in the composition and uses of the invention include the family of dimeric proteins having endochondral bone activity when implanted in a mammal in association with a matrix and which comprise a subclass of the "super family" of "TGF β -like" proteins. The natural-sourced osteogenic protein in its mature, native form is a glycosylated dimer typically having an apparent molecular weight of about 30-36 kDa as determined by SDS-PAGE. When reduced, the 30 kDa protein gives rise to two glycosylated peptide subunits having apparent molecular weights of about 16 kDa and 18 kDa. In the reduced state, the protein has no detectable osteogenic activity. The unglycosylated protein, which also has osteogenic activity, has an apparent molecular weight of about 27 kDa. When reduced, the 27 kDa protein gives rise to two unglycosylated polypeptides having molecular weights of about 14 kDa to 16 kDa capable of inducing endochondral bone formation in a mammal. Useful sequences include those comprising the C-terminal 102 amino acid sequences of DPP (from *Drosophila*), Vgl (from *Xenopus*), Vgr-1 (from mouse), the OP1 and on proteins, proteins (see U.S. Pat No. 5,011,691 and Oppermann et al., as well as the proteins referred to as BMP2, BMP3, BMP4 (see W088/00205. U. S. Patent No. 5,013,649 and W091/18098), BMP5 and BMP6 (see WO90/11366, PCT/US90/01630 and BMP8 and 9).

[0059] The members of this family of proteins share a conserved six or seven cysteine skeleton in the C-terminal

region. See, for example, 335-431 of Seq. ID No. 1 and whose sequence defines the six cysteine skeleton residues referred to herein as "OPS", or residues 330-431 of Seq. ID No. 1. comprising 102 amino acids and whose sequence defines the seven cysteine, skeleton.

[0060] This family of proteins includes longer forms of a given protein, as well as phylogenetic. e.g., species and allelic variants and biosynthetic mutants, including addition and deletion mutants and variants, such as those which may alter the conserved C-terminal cysteine skeleton, provided that the alteration still allows the protein to form a dimeric species having a conformation capable of inducing bone formation in a mammal when implanted in the mammal in association with a matrix. In addition, the osteogenic proteins useful in devices of this invention may include forms having varying glycosylation patterns and varying N-termini, may be naturally occurring or biosynthetically derived, and may be produced by expression of recombinant DNA in procaryotic or eucaryotic host cells. The proteins are active as a single species (e.g., as homodimers), or combined as a mixed species, including heterodimers.

[0061] In one embodiment, the osteogenic protein contemplated herein comprises OP1 or an OP1-related sequence. Useful OP1 sequences are recited in US Pat Nos. 5,011,691; 5,108,753 and 5,266,683; in Ozkaynak et al. (1990) EMBOJ 9:2085-2093; and Sampath et al. (1993) PNAS 90: 6004-6008. OP-1 related sequences include xenogenic homologs, e.g., 60A, from Drosophila, Wharton et al. (1991) PNAS 88:9214-9218; and proteins sharing greater than 60% identity with OP1 in the C-terminal seven cysteine domain, preferably at least 65% identity. Examples of OP-1 related sequences include BMP5, BMP6 (and its species homolog Vgr-I, Lyons et al. (1989) PNAS 86:4554-4558). Celeste, et al. (1990) PNAS 87:9843-9847 and PCT international application W093/00432; OP-2 (Sampath et al. (1990) J.Biol. Chem. 267: 13198-13205) As will be appreciated by those having ordinary skill in the art, chimeric constructs readily can be created using standard molecular biology and mutagenesis techniques combining various portions of different morphogenic protein sequences to create a novel sequence, and these forms of the protein also are contemplated herein.

[0062] In another preferred aspect, the invention contemplates osteogenic proteins comprising species of polypeptide chains having the generic amino acid sequence herein referred to as "OPX" which accommodates the homologies between the various identified species of the osteogenic OP1 and OP2 proteins, and which is described by the amino acid sequence presented below and in Sequence ID No. 3.

Cys Xaa Xaa His Glu Leu Tyr Val Ser Phe

1 5 10

Xaa Asp Leu Gly Trp Xaa Asp Trp Xaa Ile

15 20

Ala Pro Xaa Gly Tyr Xaa Ala Tyr Tyr Cys

25 30

Glu Gly Glu Cys Xaa Phe Pro Leu Xaa Ser

5 35 40

Xaa Met Asn Ala Thr Asn His Ala Ile Xaa

10 45 50

Gln Xaa Leu Val His Xaa Xaa Xaa Pro Xaa

15 55 60

Xaa Val Pro Lys Xaa Cys Cys Ala Pro Thr

20 65 70

Xaa Leu Xaa Ala Xaa Ser Val Leu Tyr Xaa

25 75 80

Asp Xaa Ser Xaa Asn Val Ile Leu Xaa Lys

30 85 90

Xaa Arg Asn Met Val Val Xaa Ala Cys Gly

35 95 100

40 Cys His,

and wherein Xaa at res. 2 = (Lys or Arg); Xaa at res. 3 = (Lys or Arg); Xaa at res. 11 = (Arg or Gln); Xaa at res. 16 = (Gln or Leu); Xaa at res. 19 = (Ile or Val); Xaa at res. 23 = (Glu or Gln); Xaa at res. 26 = (Ala or Ser); Xaa at res. 35 = (Ala or Ser); Xaa at res. 39 = (Asn or Asp); Xaa at res. 41 = (Tyr or Cys); Xaa at res. 50 = (Val or Leu); Xaa at res. 52 = (Ser or Thr); Xaa at res. 56 = (Phe or Leu); Xaa at res. 57 = (Ile or Met); Xaa at res. 58 = (Asn or Lys); Xaa at res. 60 = (Glu. Asp or Asn); Xaa at res. 61 = (Thr, Ala or Val); Xaa at res. 65 = (Pro or Ala); Xaa at res. 71 = (Gln or Lys); Xaa at res. 73 = (Asn or Ser); Xaa at res. 75 = (Ile or Thr); Xaa at res. 80 = (Phe or Tyr); Xaa at res. 82 = (Asp or Ser); Xaa at res. 84 = (Ser or Asn); Xaa at res. 89 = (Lys or Arg); Xaa at res. 91 = (Tyr or His); and Xaa at res. 97 = (Arg or Lys).

[0063] In still another preferred aspect, one or both of the polypeptide chain subunits of the osteogenically active dimer is encoded by nucleic acids which hybridize to DNA or RNA sequences encoding the active region of OP1 under stringent hybridization conditions. As used herein, stringent hybridization conditions are defined as hybridization in 40% formamide, 5 X SSPE, 5 X Denhardt's Solution, and 0.1% SDS at 37°C overnight, and washing in 0.1 X SSPE, 0.1% SDS at 50°C.

[0064] Given the foregoing amino acid and DNA sequence information, the level of skill in the art, and the disclosures of numerous publications on osteogenic proteins, including U.S. Patent 5,011,691 and published PCT specification US 89/01469, published October 19, 1989, various DNAs can be constructed which encode at least the active domain of an osteogenic protein useful in the devices of this invention, and various analogs thereof (including species and allelic

variants and those containing genetically engineered mutations), as well as fusion proteins, truncated forms of the mature proteins, deletion and addition mutants, and similar constructs which can be used in the devices and methods of the invention. Moreover, DNA hybridization probes can be constructed from fragments of any of these proteins, or designed de novo from the generic sequence. These probes then can be used to screen different genomic and cDNA libraries to identify additional osteogenic proteins useful in the prosthetic devices of this invention.

[0065] The DNAs can be produced by those skilled in the art using well known DNA manipulation techniques involving genomic and cDNA isolation, construction of synthetic DNA from synthesized oligonucleotides, and cassette mutagenesis techniques. 15-100mer oligonucleotides may be synthesized on a DNA synthesizer, and purified by polyacrylamide gel electrophoresis (PAGE) in Tris-Borate-EDTA buffer. The DNA then may be electroeluted from the gel. Overlapping oligomers may be phosphorylated by T4 polynucleotide kinase and ligated into larger blocks which may also be purified by PAGE.

[0066] The DNA from appropriately identified clones then can be isolated, subcloned (preferably into an expression vector), and sequenced. Plasmids containing sequences of interest then can be transfected into an appropriate host cell for protein expression and further characterization. The host may be a procaryotic or eucaryotic cell since the former's inability to glycosylate protein will not destroy the protein's morphogenic activity. Useful host cells include E. coli, Saccharomyces, the insect/baculovirus cell system, myeloma cells, CHO cells and various other mammalian cells. The vectors additionally may encode various sequences to promote correct expression of the recombinant protein, including transcription promoter and termination sequences, enhancer sequences, preferred ribosome binding site sequences, preferred mRNA leader sequences preferred signal sequences for protein secretion, and the like.

[0067] The DNA sequence encoding the gene of interest also may be manipulated to remove potentially inhibiting sequences or to minimize unwanted secondary structure formation. The recombinant osteogenic protein also may be expressed as a fusion protein. After being translated, the protein may be purified from the cells themselves or recovered from the culture medium. All biologically active protein forms comprise dimeric species joined by disulfide bonds or otherwise associated, produced by folding and oxidizing one or more of the various recombinant polypeptide chains within an appropriate eucaryotic cell or in vitro after expression of individual subunits. A detailed description of osteogenic proteins expressed from recombinant DNA in E. coli and in numerous different mammalian cells is disclosed in U.S. Patent No. 5,266,963.

[0068] Alternatively, osteogenic polypeptide chains can be synthesized chemically using conventional peptide synthesis techniques well known to those having ordinary skill in the art. For example, the proteins may be synthesized intact or in parts on a solid phase peptide synthesizer, using standard operating procedures. Completed chains then are deprotected and purified by HPLC (high pressure liquid chromatography). If the protein is synthesized in parts, the parts may be peptide bonded using standard methodologies to form the intact protein. In general, the manner in which the osteogenic proteins are made can be conventional and does not form a part of this invention.

Exemplification

[0069] The means for making and using the matrices and devices of the invention, as well as other material aspects concerning the nature and utility of these compositions including how to make and how to use the subject matter claimed, will be further understood from the following, which constitutes the best mode currently contemplated for practicing the invention. It will be appreciated that the invention is not limited to such exemplary work or to the specific details set forth in these examples.

[0070] In the exemplification, a hemi-joint reconstruction of an articulating synovial joint is resected into an existing joint locus. As will be appreciated by those having ordinary skill in the art, the methods and compositions of the invention equally can be applied to the formation of replacement body parts other than skeletal joints, as well as to skeletal joints other than articulating or synovial joints. Moreover, if desired, a replacement autogenous joint can be constructed in the recipient first by placing the device of the invention at another convenient locus distal to the defect site, for a time sufficient to induce formation of the replacement body part, and the autogenous body part thus formed then sutured into the joint locus for use.

Example 1. Reconstruction of a Mammalian Hemi-Joint

[0071] New Zealand white rabbits were used as the experimental model. Standard orthopedic surgical equipment and procedures were used.

[0072] As depicted in Fig. 2A, joint defects were created in a recipient by surgically resecting the entire gleno-humeral hemiarticular complex with the proximal two-thirds of the humerus. Allografts for implantation were prepared from hemi-joints excised from a donor animal with the articular surface of the glenohumeral joint. All allografts were extracted in ethanol and lyophilized using standard procedures, and as described herein above, to destroy the pathogenicity and antigenicity of the material. Specifically, intact joint complexes were excised, demarrowed and ethanol treated by

exposure to 200ml-500ml of 200 proof ethanol for 72 hours at 40 C. Fresh ethanol was provided every 6-8 hours. Following ethanol treatment, the matrix was lyophilized and rehydrated in ethanol/TFA. with or without osteogenic protein. The treated hemi-joints comprised devitalized bone, articular cartilage, ligament, tendon, synovialcapsule and synovial membrane tissue.

[0073] As illustrated in Fig. 2B, all lyophilized, osteogenic protein-treated allografts were coated with OP-1 as described in U.S. 5,011,691. Specifically, mature, dimeric recombinant OP-1 (ThOP1) was solubilized in an acetonitrile trifluoroacetic acid solution, combined with the lyophilized allograft, and implanted. 15-20 mg protein/8-10 g matrix, dry weight, was used. The distal bone portions of all allografts were secured in place with a four hole titanium miniplate. A meticulous surgical reconstruction of the joint capsule was performed by suturing the lyophilized capsule ends to the endogenous capsule using standard surgical procedures well established in the art using standard surgical procedures well established in the art. This recreated an intact capsule and synovial lining, thereby restoring the synovial milieu of the grafted articular surface. Motion was permitted almost immediately after surgery, again to restore normal joint conditions.

[0074] In some animals, local muscle flaps (cutaneous maximus muscle; Fig. 2C) were incorporated into the region of the defect by threading muscle into the marrow cavity of the allograft as depicted in Fig. 2D, using the method of Khouri as described in U.S. 5,067,963. Briefly, vascularized and convenient muscle flaps were dissected using standard procedures well known to the practitioner in reconstructive surgery, so as to maintain a perfusing blood supply, and threaded inside the bone marrow cavities of the allografts.

[0075] Preliminary evaluations of the reconstructed hemi-joints were obtained by serial weekly radiographs using X-ray, and/or magnetic resonance imaging (MRI). Histological and mechanical confirmatory evaluations were conducted upon sacrifice at 5 weeks and 6 months after surgery.

[0076] Mechanical evaluations involved standard range of motion (ROM) measurements obtained serially until sacrifice. Histological evaluations involved staining sagittal sections through the harvested allografts using standard techniques.

[0077] Briefly, identification of bona fide articular cartilage can be accomplished using ultrastructural and/or biochemical parameters. For example, articular cartilage forms a continuous layer of cartilage tissue possessing identifiable zones. The superficial zone is characterized by chondrocytes having a flattened morphology and an extracellular network which does not stain, or stains poorly, with toluidine blue, indicating the relative absence of sulphated proteoglycans. Chondrocytes in the mid and deep zones have a spherical appearance and the matrix contains abundant sulphated proteoglycans, as evidenced by staining with toluidine blue. Collagen fibers are present diffusely throughout the matrix. The chondrocytes possess abundant rough endoplasmic reticulum and are surrounded by extracellular network. The pericellular network contains numerous thin non-banded collagen fibers. The collagen in the interterritorial network is less compacted and embedded in electron translucent amorphous material similar to articular cartilage. Collagen fibers in the interterritorial region of the network exhibit the periodic banding characteristic of collagen fibers in the interterritorial zone of cartilage tissue.

[0078] Biochemically, the presence of Type II and Type IX collagen in the cartilage tissue is indicative of the differentiated phenotype of chondrocytes. The presence of Type II and/or Type IX collagen can be determined by standard gel electrophoresis, Western blot analysis and/or immunohisto-chemical staining using, for example, commercially available antibody. Other biochemical markers include hematoxylin, eosin. Goldner's Trichrome and Safranin-O.

[0079] Articular cartilage regeneration was evaluated histologically in the examples described herein using glycosaminoglycan-specific stains and techniques well-known in the art. For the initial histologic evaluation, the defect sites were bisected lengthwise through the center of the defect. The resulting halves and surrounding tissue were embedded in paraffin and sectioned across the center of the defect. One half of each defect was utilized for histological staining with toluidine blue and/or hematoxlin and eosin. Goldner's Trichrome and Safranin-O. The other half was used in preparing sections for immunostaining. Histological evaluations involved assessment of: glycosaminoglycan content in the repair cartilage; cartilage and chondrocyte morphology; and, structural integrity and morphology at the defect interface. The morphology of the repair cartilage was exhibited for the type of cartilage formed: articular vs. fibrotic by evaluating glycosaminoglycan content, degree of cartilage deposition, and the like.

[0080] Histological evaluations using standard methodologies well characterized in the art also allows assessment of new bone and bone marrow formation. See, for example, US Pat.No. 5,266,683. Similarly, ligament and synovial capsule integrity can be monitored by MRI, as well as by histology upon sacrifice.

Example 2 Five Weeks Duration (Short Term)

[0081] For the 5 week study, four groups with 10 rabbits per group were implanted with lyophilized allografts. See Figs. 3A, 3B, 3C, and 3D. In Group 1, control lyophilized allograft 30 free of osteogenic protein, was implanted (Fig. 3A). In Group 2, experimental lyophilized allograft 31 was impregnated with OP-1 prior to implantation (Fig. 3B). In Group 3, control lyophilized allograft 30 free of osteogenic protein, was implanted, with muscle flap 32 threaded into marrow cavity 33 (Fig. 3C). In Group 4, experimental lyophilized allograft 31 was impregnated with OP-1 prior to implantation, and

muscle flap 32 was threaded within the marrow cavity 33 (Fig. 3D).

[0082] As stated above, graft healing was followed non-invasively with serial X-rays and standard MRI (magnetic resonance imaging). By X-ray assessment, allografts treated with osteogenic protein had a noticeably thickened cortex by 1 week post-operative, as compared with control allografts (Groups 1, 3) which evidenced only a thin egg-shell-like cortex. By four weeks the majority control allografts had fractured and were unstable. In contrast, OP-1 treated allografts (Groups 2, 4) remained stable.

[0083] MRI also was used as a non-invasive means for following reformation of articular cartilage in the allografts. A dark signal produced by MRI represents absent or nonviable cartilage, while a bright signal indicates live, viable cartilage. Control allografts produced only a dark signal, when tested at 1, 3 and 5 weeks post-operative. These MRI findings were confirmed by histological analysis performed at 5 weeks post-operative. Sagittal sectioning through control allografts showed a degenerated articular surface with no live cells.

[0084] By contrast, the MRI findings of the articular caps from OP-1-treated allografts showed a bright signal by week 3 post-operative, indicating regeneration of viable articular cartilage. Histological analysis of the OP-1-treated allografts at week 5 revealed a layer of newly generated articular cartilage on top of the allograft matrix. The allografts of Group 4 showed somewhat thicker cartilage layers than those of Group 2, suggesting that the addition of the muscle flap may further enhance the rate of joint regeneration.

[0085] Additionally, joints regenerated with the OP-1-treated allografts regained near normal range of motion by the time they were harvested at 5 weeks post-reconstruction. The near normal range of motion also is indicative of the presence of lubricating synovial fluid. By contrast, the harvested control allografts were stiff and contracted at harvest. Thus, hemi-joint replacement devices of the invention succeeded in forming mechanically and functionally viable replacement joints, with an intact capsule, and synovium, and functioning ligament, bone and articular cartilage tissue. In the absence of osteogenic protein, the allografts, while not rejected by the donor, are insufficient on their own to generate a functional, weight bearing joint.

Example 3 Six Months Duration - (Long Term)

[0086] For the 6 month study, the variable of shaving off the old cartilaginous cap in the lyophilized allografts was introduced. Briefly, this was accomplished by mechanically sharing the articular cartilage cap of the joint surface.

[0087] The following groups were used with 4 rabbits per group: in Group 5, lyophilized allograft 34 with shaved articular surface, and muscle flap 32 were implanted (see Fig. 4A); in Group 6, control lyophilized allograft 30 with non-shaved articular surface, and muscle flap 32 were implanted (see Fig. 4B); in Group 7, lyophilized allograft 35 with shaved articular surface and OP-1, and muscle flap 36 treated with OP-1 were implanted (see Fig. 4C); and, in Group 8, lyophilized allograft 37 with a non-shaved articular surface and OP-1, and muscle flap 36 treated with OP-1 were implanted (see Fig. 4D). Grafts in Groups 5-8 were harvested at 6 months after surgery.

[0088] Based upon pre-harvest imaging studies, the results collected by 3 months post-operative are consistent with the above-described results collected at 5 weeks. Intact allografts treated with OP-1 (Group 8) regenerated a live cartilaginous articular surface by 3 weeks when evaluated using MR1. This articular cap is still present and even better developed at 3 months. Without OP-1 treatment of the allograft, (Group 6) there was negligible cartilage regeneration relative to the OP-1 treated groups.

[0089] Similarly, Group 8 rabbits (allograft + OP1, non-shaved) regained near normal range of motion (greater than 80%) in the reconstructed joint. Group 7 rabbits (allograft + OP1, shaved) achieved only 50% range of motion, and Groups 5 and 6 (no OP1) achieved less than 30%.

[0090] As determined by histology, the devices of the invention were competent to induce and maintain both bone and articular cartilage formation in the appropriate context to one another in a long term study (greater than 6 months). Specifically, the rabbits of Group 8, demonstrated articular cartilage formation on the surface of bone, as evidenced morphologically by the presence of resting, central and deeper zone chondrocytes. By contrast, in groups treated only with muscle flap, (Group 5 and 6) muscle was replaced with scar tissue. In the groups treated with shaved bone matrices, no significant cartilage regeneration was identified, demonstrating the requirement for cartilage-specific residues in articular cartilage formation in a non-vascularized milieu.

[0091] In both the short term and long term study, mechanically and functionally viable synovial joints resulted from the reconstructed hemijoints treated with osteogenic protein, as evidenced by morphology and biochemistry. In addition, new tissue formed, including articular cartilage, corresponding in shape, kind and structural relationship to the residues in the devitalized tissue which formed the matrix of the device. Collectively, these examples demonstrate that a device comprising osteogenic protein and an off-the-shelf, non-viable lyophilized, devitalized matrix can be transformed into a viable, mechanically and structurally functional replacement body part structure comprising plural distinct newly formed tissues which assume the shape and function of the original tissue. The device can restore normal function to a destroyed body part, including a destroyed skeletal joint, restoring mechanically and functionally viable plural distinct tissues, including bone and bone marrow, articular cartilage, ligament, tendon, synovial capsule and synovial membrane tissue.

Moreover, these tissues are restored under substantially physiological conditions including, for example, from responding cells present in a synovial environment, and without exposure to avascularized muscle flap.

[0092] A device comprising osteogenic protein-treated matrices, including lyophilized allografts or xenografts as disclosed herein can lead to the formation of a new, mechanically, structurally and functionally viable replacement tissue, and to replacement body parts comprising plural distinct tissues, populated by the host cells, and without any of the limitations of prosthetic materials.

[0093] Those skilled in the art will know, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. These and all other equivalents are intended to be encompassed by the following claims.

SEQUENCE LISTING

[0094]

(1) GENERAL INFORMATION:

(i) APPLICANT:

(A) NAME: CREATIVE BIOMOLCULES, INC
(B) STREET: 45 SOUTH STREET
(C) CITY: HOPKINTON
(D) STATE: MA
(E) COUNTRY: USA
(F) POSTAL CODE (ZIP): 01748
(G) TELEPHONE: (508)-435-9001
(H) TELEFAX: (508)-435-0992
(I) TELEX:

(ii) TITLE OF INVENTION: MANUFACTURE OF AUTOGENOUS REPLACEMENT BODY PARTS

(iii) NUMBER OF SEQUENCES: 3

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: PATENT ADMINISTRATOR, TESTA, HURWITZ & THIBEAULT
(B) STREET: 53 STATE STREET
(C) CITY: BOSTON
(D) STATE: MA
(E) COUNTRY: USA
(F) ZIP: 02109

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0. Version #1.25

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER: US
(B) FILING DATE:
(C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER:
(B) FILING DATE:

(viii) ATTORNEY/AGENT INFORMATION:

- (A) NAME: KELLEY, ROBIN D.
(B) REGISTRATION NUMBER: 34,637
(C) REFERENCE/DOCKET NUMBER: CRP101PC

(ix) TELECOMMUNICATION INFORMATION:

- (A) TELEPHONE: 617/248-7000
(B) TELEFAX: 617/248-7100

(2) INFORMATION FOR SEQ ID NO:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1822 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: HOMO SAPIENS
(F) TISSUE TYPE: HIPPOCAMPUS

(ix) FEATURE:

- (A) NAME/KEY: CDS
(B) LOCATION: 49..1341
(C) IDENTIFICATION METHOD: experimental
(D) OTHER INFORMATION: /function= "OSTEOGENIC PROTEIN-
/product= "OP1"
/evidence= EXPERIMENTAL
/standard_name= " OP1 "

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

EP 0 762 903 B2

	GGTGC	GGGCC	CGGAG	CCCGG	AGCCC	GGGTA	GCGCG	TAGAG	CCGGC	GCG	ATG	CAC	GTG	57			
											Met	His	Val				
											1						
5																	
	CGC	TCA	CTG	CGA	GCT	GCG	GCG	CCG	CAC	AGC	TTC	GTG	GCG	CTC	TGG	GCA	105
	Arg	Ser	Leu	Arg	Ala	Ala	Ala	Pro	His	Ser	Phe	Val	Ala	Leu	Trp	Ala	
		5					10					15					
10	CCC	CTG	TTC	CTG	CTG	CGC	TCC	GCC	CTG	GCC	GAC	TTC	AGC	CTG	GAC	AAC	153
	Pro	Leu	Phe	Leu	Leu	Arg	Ser	Ala	Leu	Ala	Asp	Phe	Ser	Leu	Asp	Asn	
	20					25					30					35	
	GAG	GTG	CAC	TCG	AGC	TTC	ATC	CAC	CGG	GCG	CTC	GCG	AGC	CAG	GAG	CGG	201
	Glu	Val	His	Ser	Ser	Phe	Ile	His	Arg	Arg	Leu	Arg	Ser	Gln	Glu	Arg	
15					40					45					50		
	CGG	GAG	ATG	CAG	GCG	GAG	ATC	CTC	TCC	ATT	TTG	GGC	TTG	CCC	CAC	CGC	249
	Arg	Glu	Met	Gln	Arg	Glu	Ile	Leu	Ser	Ile	Leu	Gly	Leu	Pro	His	Arg	
				55					60					65			
20	CCG	GCG	CCG	CAC	CTC	CAG	GGC	AAG	CAC	AAC	TCG	GCA	CCC	ATG	TTC	ATG	297
	Pro	Arg	Pro	His	Leu	Gln	Gly	Lys	His	Asn	Ser	Ala	Pro	Met	Phe	Met	
			70					75					80				
	CTG	GAC	CTG	TAC	AAC	GCC	ATG	GCG	GTG	GAG	GAG	GGC	GGC	GGG	CCC	GCG	345
	Leu	Asp	Leu	Tyr	Asn	Ala	Met	Ala	Val	Glu	Glu	Gly	Gly	Gly	Pro	Gly	
25		85					90					95					
	GGC	CAG	GGC	TTC	TCC	TAC	CCC	TAC	AAG	GCC	GTG	TTC	AGT	ACC	CAG	GCG	393
	Gly	Gln	Gly	Phe	Ser	Tyr	Pro	Tyr	Lys	Ala	Val	Phe	Ser	Thr	Gln	Gly	
	100					105					110					115	
30	CCC	CCT	CTG	GCC	AGC	CTG	CAA	GAT	AGC	CAT	TTC	CTC	ACC	GAC	GCC	GAC	441
	Pro	Pro	Leu	Ala	Ser	Leu	Gln	Asp	Ser	His	Phe	Leu	Thr	Asp	Ala	Asp	
					120					125					130		
	ATG	GTC	ATG	AGC	TTC	GTC	AAC	CTC	GTG	GAA	CAT	GAC	AAG	GAA	TTC	TTC	489
	Met	Val	Met	Ser	Phe	Val	Asn	Leu	Val	Glu	His	Asp	Lys	Glu	Phe	Phe	
35				135					140					145			
	CAC	CCA	GCG	TAC	CAC	CAT	CGA	GAG	TTC	CGG	TTT	GAT	CTT	TCC	AAG	ATC	537
	His	Pro	Arg	Tyr	His	His	Arg	Glu	Phe	Arg	Phe	Asp	Leu	Ser	Lys	Ile	

40

45

50

55

EP 0 762 903 B2

	150	155	160	
5	CCA GAA GGG GAA GCT GTC Pro Glu Gly Glu Ala Val 165	ACG GCA GCC GAA TTC Thr Ala Ala Glu Phe 170	CGG ATC TAC AAG GAC Arg Ile Tyr Lys Asp 175	585
	TAC ATC CGG GAA CGC Tyr Ile Arg Glu Arg 180	TTC GAC AAT GAG ACG Phe Asp Asn Glu Thr 185	TTC CGG ATC AGC GTT TAT Phe Arg Ile Ser Val Tyr 190	633
10	CAG GTG CTC CAG GAG Gln Val Leu Gln Glu 200	CAC TTG GGC AGG GAA His Leu Gly Arg Glu 205	TCG GAT CTC TTC CTG CTC Ser Asp Leu Phe Leu Leu 210	681
15	GAC AGC CGT ACC CTC Asp Ser Arg Thr Leu 215	TGG GCC TCG GAG GAG Trp Ala Ser Glu Glu 220	GGC TCG CTG GTG TTT GAC Gly Trp Leu Val Phe Asp 225	729
	ATC ACA GCC ACC AGC Ile Thr Ala Thr Ser 230	AAC CAC TGG GTG GTC Asn His Trp Val Val 235	AAT CCG CGG CAC AAC CTG Asn Pro Arg His Asn Leu 240	777
20	GGC CTG CAG CTC TCG Gly Leu Gln Leu Ser 245	GTG GAG ACG CTG GAT Val Glu Thr Leu Asp 250	GGG CAG AGC ATC AAC CCC Gly Gln Ser Ile Asn Pro 255	825
25	AAG TTG GCG GGC CTG Lys Leu Ala Gly Leu 260	ATT GGG CGG CAC GGG Ile Gly Arg His Gly 265	CCC CAG AAC AAG CAG CCC Pro Gln Asn Lys Gln Pro 270	873
	TTC ATG GTG GCT TTC Phe Met Val Ala Phe 280	TTC AAG GCC ACG GAG Phe Lys Ala Thr Glu 285	GTC CAC TTC CGC AGC ATC Val His Phe Arg Ser Ile 290	921
30	CGG TCC ACG GGG AGC Arg Ser Thr Gly Ser 295	AAA CAG CGC AGC CAG Lys Gln Arg Ser Gln 300	AAC CGC TCC AAG ACG CCC Asn Arg Ser Lys Thr Pro 305	969
	AAG AAC CAG GAA GCC Lys Asn Gln Glu Ala 310	CTG CGG ATG GCC AAC Leu Arg Met Ala Asn 315	GTG GCA GAG AAC AGC AGC Val Ala Glu Asn Ser Ser 320	1017
35	AGC GAC CAG AGG CAG Ser Asp Gln Arg Gln 325	GCC TGT AAG AAG CAC Ala Cys Lys Lys His 330	GAG CTG TAT GTC AGC TTC Glu Leu Tyr Val Ser Phe 335	1065
40	CGA GAC CTG GGC TGG Arg Asp Leu Gly Trp 340	CAG GAC TGG ATC ATC Gln Asp Trp Ile Ile 345	GCG CCT GAA GGC TAC GCC Ala Pro Glu Gly Tyr Ala 350	1113
	GCC TAC TAC TGT GAG Ala Tyr Tyr Cys Glu 360	GGG GAG TGT GCC TTC Gly Glu Cys Ala Phe 365	CCT CTG AAC TCC TAC ATG Pro Leu Asn Ser Tyr Met 370	1161
45	AAC GCC ACC AAC CAC Asn Ala Thr Asn His 375	GCC ATC GTG CAG ACG Ala Ile Val Gln Thr 380	CTG GTC CAC TTC ATC AAC Leu Val His Phe Ile Asn 385	1209
50	CCG GAA ACG GTG CCC Pro Glu Thr Val Pro 390	AAG CCC TGC TGT GCG Lys Pro Cys Cys Ala 395	ACG CAG CTC AAT GCC Thr Gln Leu Asn Ala 400	1257
55	ATC TCC GTC CTC TAC Ile Ser Val Leu Tyr 410	TTC GAT GAC AGC TCC Phe Asp Asp Ser Ser 415	AAC GTC ATC CTG AAG AAA Asn Val Ile Leu Lys Lys 420	1305

EP 0 762 903 B2

	405	410	415	
5	TAC AGA AAC ATG GTG GTC CGG GCC TGT GGC TGC CAC TAGCTCCTCC			1351
	Tyr Arg Asn Met Val Val Arg Ala Cys Gly Cys His			
	420	425	430	
	GAGAATTCAG ACCCTTTGGG GCCAAGTTTT TCTGGATCCT CCATTGCTCG CCTTGGCCAG			1411
10	GAACCAGCAG ACCAACTGCC TTTTGTGAGA CCTTCCCCTC CCTATCCCCA ACTTTAAAGG			1471
	TGTGAGAGTA TTAGGAAACA TGAGCAGCAT ATGGCTTTTG ATCAGTTTTT CAGTGGCAGC			1531
	ATCCAATGAA CAAGATCCTA CAAGCTGTGC AGGCAAAACC TAGCAGGAAA AAAAAACAAC			1591
15	GCATAAGAA AAATGGCCGG GCCAGGTCAT TGGCTGGGAA GTCTCAGCCA TGCACGGACT			1651
	CGTTTCACGA GGTAAATTATG AGCGCCTACC AGCCAGGCCA CCCAGCCGTG GGAGGAAGGG			1711
	GGCGTGGCAA GGGGTGGGCA CATTTGGTGTG TGTGCGAAAG GAAAATTGAC CCGGAAGTTC			1771
20	CTGTAATAAA TGTACAATA AAACGAATGA ATGAAAAAAAA AAAAAAAAAA A			1822

(2) INFORMATION FOR SEQ ID NO:2:

25 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 431 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

35

40

45

50

55

EP 0 762 903 B2

Met His Val Arg Ser Leu Arg Ala Ala Ala Pro His Ser Phe Val Ala
 1 5 10 15
 5 Leu Trp Ala Pro Leu Phe Leu Leu Arg Ser Ala Leu Ala Asp Phe Ser
 20 25 30
 Leu Asp Asn Glu Val His Ser Ser Phe Ile His Arg Arg Leu Arg Ser
 35 40 45
 10 Gln Glu Arg Arg Glu Met Gln Arg Glu Ile Leu Ser Ile Leu Gly Leu
 50 55 60
 Pro His Arg Pro Arg Pro His Leu Gln Gly Lys His Asn Ser Ala Pro
 65 70 75 80
 15 Met Phe Met Leu Asp Leu Tyr Asn Ala Met Ala Val Glu Glu Gly Gly
 85 90 95
 Gly Pro Gly Gly Gln Gly Phe Ser Tyr Pro Tyr Lys Ala Val Phe Ser
 100 105 110
 20 Thr Gln Gly Pro Pro Leu Ala Ser Leu Gln Asp Ser His Phe Leu Thr
 115 120 125
 Asp Ala Asp Met Val Met Ser Phe Val Asn Leu Val Glu His Asp Lys
 130 135 140
 25 Glu Phe Phe His Pro Arg Tyr His His Arg Glu Phe Arg Phe Asp Leu
 145 150 155 160

30

35

40

45

50

55

EP 0 762 903 B2

Ser Lys Ile Pro Glu Gly Glu Ala Val Thr Ala Ala Glu Phe Arg Ile
 165 170 175
 Tyr Lys Asp Tyr Ile Arg Glu Arg Phe Asp Asn Glu Thr Phe Arg Ile
 180 185 190
 Ser Val Tyr Gln Val Leu Gln Glu His Leu Gly Arg Glu Ser Asp Leu
 195 200 205
 Phe Leu Leu Asp Ser Arg Thr Leu Trp Ala Ser Glu Glu Gly Trp Leu
 210 215 220
 Val Phe Asp Ile Thr Ala Thr Ser Asn His Trp Val Val Asn Pro Arg
 225 230 235 240
 His Asn Leu Gly Leu Gln Leu Ser Val Glu Thr Leu Asp Gly Gln Ser
 245 250 255
 Ile Asn Pro Lys Leu Ala Gly Leu Ile Gly Arg His Gly Pro Gln Asn
 260 265 270
 Lys Gln Pro Phe Met Val Ala Phe Phe Lys Ala Thr Glu Val His Phe
 275 280 285
 Arg Ser Ile Arg Ser Thr Gly Ser Lys Gln Arg Ser Gln Asn Arg Ser
 290 295 300
 Lys Thr Pro Lys Asn Gln Glu Ala Leu Arg Met Ala Asn Val Ala Glu
 305 310 315 320
 Asn Ser Ser Ser Asp Gln Arg Gln Ala Cys Lys Lys His Glu Leu Tyr
 325 330 335
 Val Ser Phe Arg Asp Leu Gly Trp Gln Asp Trp Ile Ile Ala Pro Glu
 340 345 350
 Gly Tyr Ala Ala Tyr Tyr Cys Glu Gly Glu Cys Ala Phe Pro Leu Asn
 355 360 365
 Ser Tyr Met Asn Ala Thr Asn His Ala Ile Val Gln Thr Leu Val His
 370 375 380
 Phe Ile Asn Pro Glu Thr Val Pro Lys Pro Cys Cys Ala Pro Thr Gln
 385 390 395 400
 Leu Asn Ala Ile Ser Val Leu Tyr Phe Asp Asp Ser Ser Asn Val Ile
 405 410 415
 Leu Lys Lys Tyr Arg Asn Met Val Val Arg Ala Cys Gly Cys His
 420 425 430

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 102 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

- (A) NAME/KEY: Protein
 (B) LOCATION: 1..102




FIG. 1




FIG. 2




FIG. 3A




FIG. 3B




FIG. 3C




FIG. 3D




FIG. 4A




FIG. 4B




FIG. 4C




FIG. 4D

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 5011691 A [0020] [0053] [0058] [0061] [0064] [0073]
- US 5266683 A [0020] [0020] [0042] [0055] [0061]
- WO 9300432 A [0020] [0061]
- US 5067963 A [0041] [0074]
- US 4968590 A [0042]
- US 5258499 A [0042]
- US 4975526 A [0053]
- US 5171574 A [0053]
- WO 8800205 A [0058]
- US 5013649 A [0058]
- WO 9118098 A [0058]
- WO 9011366 A [0058]
- US 9001630 W [0058]
- US 5108753 A [0061]
- US 8901469 W [0064]
- US 5266963 A [0067]

Non-patent literature cited in the description

- GRAY. *Anatomy of the Human Body*. 1985, vol. 312, 333-336 [0002]
- AYDELOTTE ; KUETTNER. *Conn. Tiss. Res.*, 1988, vol. 18, 205 [0009]
- ZANETTI et al. *J. Cell Biol.*, 1985, vol. 101, 53 [0009]
- POOLE et al. *J. Anat.*, 1984, vol. 138, 13 [0009]
- OZKAYNAK et al. *EMBO J*, 1990, vol. 9, 2085-2093 [0020]
- WHARTON et al. *PNAS*, 1991, vol. 88, 9214-9218 [0020] [0061]
- OZKAYNAK. *J. Biol. Chem.*, 1992, vol. 267, 25220-25227 [0020]
- CELESTE et al. *PNAS*, 1990, vol. 87, 9843-9847 [0020] [0061]
- LYONS et al. *PNAS*, 1989, vol. 86, 4554-4558 [0020] [0061]
- WOZNEY et al. *Science*, 1988, vol. 242, 1528-1533 [0020]
- PADGETT et al. *Nature*, 1987, vol. 325, 81-84 [0020]
- WEEKS. *Cell*, 1987, vol. 51, 861-867 [0020]
- SAMPATH et al. *PNAS*, 1983, vol. 80, 6591-6595 [0053]
- OZKAYNAK et al. *EMBOJ*, 1990, vol. 9, 2085-2093 [0061]
- SAMPATH et al. *PNAS*, 1993, vol. 90, 6004-6008 [0061]
- SAMPATH et al. *J.Biol.*, 1990, vol. Chem., 13198-13205 [0061]

(D) OTHER INFORMATION: /label= OPX

/note= "WHEREIN EACH XAA IS INDEPENDENTLY SELECTED FROM A GROUP OF ONE OR MORE SPECIFIED AMINO ACIDS AS DEFINED IN THE SPECIFICATION"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

```

Cys Xaa Xaa His Glu Leu Tyr Val Xaa Phe Xaa Asp Leu Gly Trp Xaa
1          5          10          15
Asp Trp Xaa Ile Ala Pro Xaa Gly Tyr Xaa Ala Tyr Tyr Cys Glu Gly
10          20          25          30
Glu Cys Xaa Phe Pro Leu Xaa Ser Xaa Met Asn Ala Thr Asn His Ala
15          35          40          45
Ile Xaa Gln Xaa Leu Val His Xaa Xaa Xaa Pro Xaa Xaa Val Pro Lys
20          50          55          60
Xaa Cys Cys Ala Pro Thr Xaa Leu Xaa Ala Xaa Ser Val Leu Tyr Xaa
25          65          70          75          80
Asp Xaa Ser Xaa Asn Val Xaa Leu Xaa Lys Xaa Arg Asn Met Val Val
30          85          90          95
Xaa Ala Cys Gly Cys His
100

```

Claims

1. A device suitable for implantation in a mammal, wherein said device comprises:

- a) a biocompatible and bioresorbable or biodegradable matrix defining a single structure that allows the attachment of infiltrating cells thereto, the matrix comprising residues derived from, plural distinct tissues of a skeletal joint, at least one of said tissues being a non-mineralized tissue; and
- b) an exogenous osteogenic protein disposed on the surface of or within said matrix,

wherein the matrix is part or all of a devitalized skeletal joint structure.

2. The device according to claim 1 suitable for implantation in a mammal to replace *in vivo* non-mineralized tissue in a skeletal joint, wherein:

- a) the skeletal joint is a hemi-joint (e.g. a proximal or distal hemi-joint) and the tissues correspond in kind to said tissue being replaced; and
- b) the attachment of infiltrating cells permits regeneration of the non-mineralized tissue in a skeletal joint.

3. Use of the matrix and osteogenic protein as defined in claim 1 or claim 2 for the manufacture of a device according to claim 1 or claim 2 for repairing a skeletal joint defect in a mammal.

4. Use of the matrix and osteogenic protein as defined in claim 1 or claim 2 for the manufacture of a device according to claim 1 or claim 2 for forming or restoring *in vivo* non-mineralized tissue in a skeletal joint in a mammal.

5. Use of the matrix and osteogenic protein as defined in claim 1 or claim 2 for the manufacture of a device according to claim 1 or claim 2 for use in a method of repairing *in vivo* a non-mineralized tissue defect in a skeletal joint of a mammal, said method comprising providing to said defect the device so as to permit the regeneration of said non-mineralized tissue therein.

6. The device according to claim 1 or claim 2 wherein the non-mineralized tissue is articular cartilage.

7. Use of the matrix and osteogenic protein as defined in claim 1 for the manufacture of a device according to claim 6 for forming *in vivo* articular cartilage in a skeletal joint or to repair *in vivo* an articular cartilage defect (e.g. on the surface of a bone) in a mammal (e.g. in a synovial cavity).
- 5 8. Use of the matrix and osteogenic protein as defined in claim 6 for the manufacture of a device according to claim 3 for use in a method of forming *in vivo* articular cartilage in a skeletal joint, said method comprising implanting the device at a locus in said mammal so as to induce formation of articular cartilage therein.
9. Use of the matrix and osteogenic protein as defined in claim 6 for the manufacture of a device according to claim 3 for use in a method of repairing *in vivo* an articular cartilage defect in a mammal (e.g. on the surface of a bone), said method comprising implanting the device in the locus of said articular cartilage defect (e.g. by providing the device to the bone surface) so as to induce formation of replacement articular cartilage therein.
- 10 10. The use of claim 9 wherein the articular cartilage defect is in a synovial cavity.
11. The device according to claim 1 suitable for serving as a template to form *in vivo* a functional skeletal joint or part thereof comprising plural distinct tissues, wherein the osteogenic protein is disposed on the surface of said matrix in an amount sufficient to induce formation of said plural distinct tissues having dimensions and shape which conform to the skeletal joint to be repaired, thereby to permit regeneration of a functional skeletal joint.
- 20 12. The device according to claim 1 suitable for forming a stable, functional, replacement skeletal joint that comprises articular cartilage and bone tissues at a skeletal joint defect site in a mammal, wherein:
 - a) the matrix is a support material excised from a mammalian donor skeletal joint, the matrix having dimensions and shape which mimic that of the skeletal joint to be replaced and comprising residues of articular cartilage and bone which are dimensioned to correspond in shape and structural relation to said plural distinct tissues to be replaced; and
 - b) the osteogenic protein is disposed on the surface of said matrix in an amount sufficient to induce formation of bone and associated articular cartilage tissues, thereby permitting the regeneration of a functional replacement skeletal joint at the defect site.
- 25 13. Use of the matrix and osteogenic protein as defined in claim 1, 11 or 12 for the manufacture of a device according to claim 1, 11 or 12 for forming a stable, functional replacement skeletal joint at a skeletal joint defect site in a mammal.
- 35 14. Use of the matrix and osteogenic protein as defined in claim 1, 11 or 12 for the manufacture of a device according to claim 1, 11 or 12 for use in a method of replacing a defective skeletal joint comprising surgically excising said defective skeletal joint and implanting the device at the site of the excision.
- 40 15. The device according to claim 11 suitable for repairing a skeletal joint defect in a mammal, wherein:
 - a) the matrix comprises plural distinct residues derived from a proximal or distal hemi-joint including at least one non-mineralized tissue of a joint; and
 - b) the osteogenic protein is disposed on, adsorbed to or precipitated onto the surface of said matrix.
- 45 16. Use of the matrix and osteogenic protein as defined in claim 15 for the manufacture of a device according to claim 15 for repairing a skeletal joint defect in a mammal.
17. Use of the matrix and osteogenic protein as defined in claim 15 for the manufacture of a device according to claim 15 for forming *in vivo* a functional replacement skeletal joint in a mammal. _
- 50 18. Use of the matrix and osteogenic protein as defined in claim 15 for the manufacture of a device according to claim 15 for use in a method of inducing in a mammal the formation *in vivo* of a replacement skeletal joint, said method comprising implanting the device at a locus in a mammal so as to induce formation of a functional replacement skeletal joint comprising plural distinct tissues therein.
- 55 19. The device according to claim 1 suitable for forming a stable, functional, vitalized articulating skeletal joint at a defect site in a mammal, wherein:

- a) the matrix is excised from a mammalian donor articulating skeletal joint;
- b) the matrix has dimensions and shape which mimic that of the skeletal joint and comprises residues which are dimensioned to correspond in shape and structural relation to said plural distinct tissues to be replaced; and
- c) the osteogenic protein is present in an amount sufficient to induce the formation of a vitalized articulating surface and vitalized plural distinct tissues thereby permitting the regeneration of a stable, functional, vitalized articulating skeletal joint at said defect site.

20. Use of the matrix and osteogenic protein as defined in claim 19 for the manufacture of a device according to claim 19 for repairing a skeletal joint defect in a mammal.

21. Use of the matrix and osteogenic protein as defined in claim 19 for the manufacture of a device according to claim 19 for restoring a stable, functional, vitalized, articulating skeletal joint at a joint defect site in a mammal.

22. Use of the matrix and osteogenic protein as defined in claim 19 for the manufacture of a device according to claim 19 for use in a method of restoring a stable, functional, vitalized, articulating skeletal joint at a joint defect site in a mammal, said method comprising providing to said joint defect site the device so as to permit the restoration of a stable, functional, vitalized, articulating skeletal joint therein.

23. The device according to claim 19 suitable for forming plural distinct non-mineralized tissues in a stable, functional, vitalized articulating skeletal joint *in vivo*, wherein said residues have specificity for, or are derived from, plural distinct non-mineralizing tissues and the osteogenic protein is present in an amount sufficient to induce the formation of an articulating surface and plural distinct non-mineralized tissues thereby permitting the regeneration of a stable, functional, vitalized articulating skeletal joint at said defect site.

24. Use of the matrix and osteogenic protein as defined in claim 23 for the manufacture of a device according to claim 23 for restoring plural distinct non-mineralized tissues in a skeletal joint in a mammal.

25. Use of the matrix and osteogenic protein as defined in claim 23 for the manufacture of a device according to claim 23 for use in a method of restoring plural distinct non-mineralized tissues in a skeletal joint in a mammal, said method comprising providing to the site of said joint the device so as to permit the restoration of a non-mineralized tissue therein.

26. The use of claim 25 wherein the non-mineralized tissue to be restored comprises avascular tissue.

27. The use of claim 25 wherein the non-mineralized tissue to be restored is selected from articular cartilage, ligament, tendon, synovial capsule, an interacting bone attachment site, a muscle to bone joint site and synovial membrane tissue.

28. The use of any one of claims 5, 8 to 10, 14, 18, 22 and 25 to 27 wherein the skeletal joint being restored or replaced is a synovial joint.

29. The use of any one of claims 5, 8 to 10, 14, 18, 22 and 25 to 28 wherein the method further comprises the step of implanting a muscle flap into a hollow portion of the matrix of the device.

30. The device according to any one of claims 1, 2, 6, 11, 12, 15, 19 and 23 or the use of any one of claims 3 to 5, 7 to 10, 13, 14, 16 to 18, 20 to 22 and 24 to 29 wherein the osteogenic protein is selected from OP-1, OP-2, OPX, BMP2, BMP4, BMP5, BMP6, BMP9, a protein comprising the C-terminal 102 amino acid sequence of DPP, Vgl, 60A, Vgr-1 or a naturally-sourced or biosynthetic or recombinant derivative thereof or a homodimer or heterodimer of any one or more of said proteins.

31. The device or use according to claim 30 wherein the osteogenic protein is OP- or a related osteogenic protein or a homodimer or heterodimer thereof.

32. The device or use according to claim 31 wherein the related osteogenic protein comprises a six or seven cysteine skeleton in the C-terminal region.

33. The device or use according to claim 31 wherein the osteogenic protein is OP-1 or a homodimer or heterodimer thereof.

34. The device according to any one of claims 1, 2, 6, 11, 12, 15, 19, 23 and 30 to 33 or the use of any one of claims 3 to 5, 7 to 10, 13, 14, 16 to 18, 20 to 22, 24 to 29 and 30 to 33 wherein the matrix is devitalized by dehydration.

35. The device or use according to claim 34 wherein the matrix comprises devitalized allogenic or xenogenic tissues.

36. The device according to any one of claims 1, 2, 6, 11, 12, 15, 19, 23 and 30 to 35 or the use of any one of claims 3 to 5, 7 to 10, 13, 14, 16 to 18, 20 to 22, 24 to 29 and 30 to 35 wherein the matrix comprises bone and associated articular cartilage excised from a allogenic or xenogenic mammalian donor skeletal joint.

37. The device or use according to any one of claims 34 to 36 wherein the matrix comprises devitalized tissue from a mammalian donor.

38. The device or use according to any one of claims 34 to 37 wherein the matrix comprises dehydrated mammalian tissue.

39. The device according to any one of claims 1, 2, 6, 11, 12, 15, 19, 23 and 30 to 38 or the use of any one of claims 3 to 5, 7 to 10, 13, 14, 16 to 18, 20 to 22, 24 to 29 and 30 to 38 wherein at least one of the plural distinct tissues (e.g. at least one of said non-mineralized tissues) is selected from articular cartilage, ligament, tendon, synovial capsule, an interacting bone attachment site, a muscle to bone joint site and synovial membrane tissue.

40. The device or use according to any one of claims 1 to 38 wherein at least one of the plural distinct tissues (e.g. the non-mineralized tissue) is an avascular tissue.

41. The device according to any one of claims 1, 2, 6, 11, 12, 15, 19, 23 and 30 to 40 or the use of any one of claims 3 to 5, 7 to 10, 13, 14, 16 to 18, 20 to 22, 24 to 29 and 30 to 40 wherein the plural distinct tissues comprise cartilage (e.g. articular cartilage) and bone.

42. The device according to any one of claims 1, 2, 6, 11, 12, 15, 19, 23 and 30 to 41 or the use of any one of claims 3 to 5, 7 to 10, 13, 14, 16 to 18, 20 to 22, 24 to 29 and 30 to 41 wherein the skeletal joint defines a synovial or articulating joint or a portion of said synovial or articulating joint.

43. The device or use according to claim 42 wherein the skeletal joint comprises or is a synovial joint.

44. The device according to any one of claims 1, 2, 6, 11, 12, 15, 19, 23 and 30 to 43 or the use of any one of claims 3 to 5, 7 to 10, 13, 14, 16 to 18, 20 to 22, 24 to 29 and 30 to 43 wherein the device further comprises a material selected from collagen, polymers comprising monomers of lactic acid, glycolic acid, butyric acid or combinations thereof; ceramics such as hydroxyapatite, tricalcium phosphate or mixtures thereof.

45. The device according to any one of claims 1, 2, 6, 11, 12, 15, 19, 23 and 30 to 44 or the use of any one of claims 3 to 5, 7 to 10, 13, 14, 16 to 18, 20 to 22, 24 to 29 and 30 to 44 wherein the device comprises a mouldable solid or further comprises a material suitable for binding particulate matter to form a mouldable solid.

46. The use according to claim 13 wherein the site defines an endogenous body part to be replaced.

47. The use according to claim 13 wherein the matrix further comprises residues which are dimensioned to correspond in shape and structural relation to said plural distinct tissues.

48. The use according to claim 4 or claim 7 wherein the matrix is derived from allogenic or xenogenic articular cartilage.

49. The use according to claim 4 or claim 7 wherein the device comprises a mouldable solid.

50. The use according to claim 4 or claim 7 wherein the device comprises a flexible sheet.

51. The use according to any one of claims 48 to 50 wherein the osteogenic protein is as defined in claim 30.

52. The device according to any one of claims 1, 2, 6, 11, 12, 15, 19, 23 and 30 to 45 for use in implantation in a mammal.

Patentansprüche

1. Vorrichtung, die zum Implantieren in ein Säugetier geeignet ist, und umfasst:

- a) eine biokompatible und bioresorbierbare oder biologisch abbaubare Matrix, die eine Einzelstruktur definiert, an der sich Infiltrationszellen anlagern können, worin die Matrix Reste umfasst, die abgeleitet sind von mehreren verschiedenen Geweben eines Skelettgelenks, wobei mindestens eines der Gewebe ein nicht nicht-mineralisiertes Gewebe ist; und
- b) ein exogenes osteogenes Protein, das sich auf der Oberfläche oder innerhalb der genannten Matrix befindet,

worin die Matrix Teil oder alles einer devitalisierten Skelettgelenk-Struktur ist.

2. Vorrichtung nach Anspruch 1, die zum Implantieren in ein Säugetier geeignet ist, um *in vivo* nicht mineralisiertes Gewebe in einem Skelettgelenk zu ersetzen, worin:

- a) das Skelettgelenk ein Halbgelenk ist (beispielsweise ein proximales oder distales Halbgelenk) und die Gewebe vom Typ dem zu ersetzenden Gewebe entsprechen; und
- b) die Anlagerung von Infiltrationszellen eine Regeneration des nicht-mineralisierten Gewebes in einem Skelettgelenk ermöglicht.

3. Verwendung der Matrix und des osteogenen Proteins nach Anspruch 1 oder Anspruch 2 zur Herstellung einer Vorrichtung nach Anspruch 1 oder Anspruch 2 zum Reparieren eines Skelettgelenkdefektes in einem Säugetier.

4. Verwendung der Matrix und des osteogenen Proteins nach Anspruch 1 oder Anspruch 2 zur Herstellung einer Vorrichtung nach Anspruch 1 oder Anspruch 2 zur *in vivo*-Bildung oder -Wiederherstellung von nicht mineralisiertem Gewebe in einem Skelettgelenk eines Säugetiers.

5. Verwendung der Matrix und des osteogenen Proteins nach Anspruch 1 oder Anspruch 2 zur Herstellung einer Vorrichtung nach Anspruch 1 oder Anspruch 2 zur Verwendung in einem Verfahren zum *in vivo*-Reparieren eines Defekts in nicht mineralisiertem Gewebe in einem Skelettgelenk eines Säugetiers, wobei das Verfahren umfasst, Bereitstellen der Vorrichtung für den Defekt, um die Regeneration des genannten nicht mineralisierten Gewebes darin zu ermöglichen.

6. Vorrichtung nach Anspruch 1 oder Anspruch 2, worin das nicht mineralisierte Gewebe Gelenkknorpel ist.

7. Verwendung der Matrix und des osteogenen Proteins nach Anspruch 1 zur Herstellung einer Vorrichtung nach Anspruch 6 zur *in vivo*-Bildung von Gelenkknorpel in einem Skelettgelenk oder zum *in vivo*-Reparieren eines Gelenkknorpeldefektes (beispielsweise auf der Oberfläche eines Knochens) in einem Säugetier (beispielsweise in einer Synovialhöhle)

8. Verwendung der Matrix und des osteogenen Proteins nach Anspruch 6 zur Herstellung einer Vorrichtung nach Anspruch 3 zur Verwendung in einem Verfahren zur *in vivo*-Bildung von Gelenkknorpel in einem Skelettgelenk, wobei das Verfahren das Implantieren der Vorrichtung an einem Ort in dem Säugetier umfasst, um die Bildung von Gelenkknorpel darin zu induzieren.

9. Verwendung der Matrix und des osteogenen Proteins nach Anspruch 6 zur Herstellung einer Vorrichtung nach Anspruch 3 zur Verwendung in einem Verfahren zum *in vivo*-Reparieren eines Gelenkknorpeldefektes in einem Säugetier (beispielsweise auf der Oberfläche eines Knochens), wobei das Verfahren umfasst, Implantieren der Vorrichtung am Ort des Gelenkknorpeldefektes (beispielsweise durch Bereitstellen der Vorrichtung an der Knochenoberfläche), um die Bildung von Ersatzgelenkknorpel darin zu induzieren.

10. Verwendung nach Anspruch 9, wobei der Gelenkknorpeldefekt in einer Synovialhöhle ist.

11. Vorrichtung nach Anspruch 1, die als Matrize zur *in vivo*-Bildung eines funktionellen Skelettgelenks oder eines Teils davon geeignet ist, umfassend, mehrere verschiedene Gewebe, wobei das osteogene Protein auf der Oberfläche der Matrix in einer Menge vorhanden ist, die ausreicht, um die Bildung der mehreren verschiedenen Gewebe zu induzieren, die Abmessungen und eine Form in Übereinstimmung mit dem zu reparierenden Skelettgelenk haben, um so die Regeneration eines funktionellen Skelettgelenks zu ermöglichen.

12. Vorrichtung nach Anspruch 1, die dafür geeignet ist, ein stabiles, funktionelles Ersatzskelettgelenk, das Gelenkknorpel und Knochengewebe umfasst, an einer Skelettgelenkdefektstelle in einem Säugetier zu bilden, wobei:

- a) die Matrix ein Trägermaterial ist, das von einem Säugetierspenderskelettgelenk exzidiert wurde, wobei die Matrix Abmessungen und eine Form aufweist, die denen/der des zu ersetzenden Skelettgelenks ähnlich sind/ist, und Reste von Gelenkknorpel und Knochen umfasst, die so bemessen sind, dass sie bezüglich Form und Strukturbeziehung den zu ersetzenden mehreren verschiedenen Geweben entsprechen; und
- b) das osteogene Protein in einer Menge auf der Oberfläche der Matrix vorliegt, die ausreicht, um die Bildung von Knochen und zugehörigem Gelenkknorpelgewebe zu induzieren, wodurch die Regeneration eines funktionellen Ersatzskelettgelenks an der defekten Stelle ermöglicht wird.

13. Verwendung der Matrix und des osteogenen Proteins nach Anspruch 1, 11 oder 12 zur Herstellung einer Vorrichtung nach Anspruch 1, 11 oder 12 zur Bildung eines stabilen, funktionellen Ersatzskelettgelenks an einer Skelettgelenkdefektstelle in einem Säugetier.

14. Verwendung der Matrix und des osteogenen Proteins nach Anspruch 1, 11 oder 12 zur Herstellung einer Vorrichtung nach Anspruch 1, 11 oder 12 zur Verwendung in einem Verfahren zum Ersetzen eines defekten Skelettgelenks, umfassend, chirurgisches Exzidieren des defekten Skelettgelenks und Implantieren der Vorrichtung in die Exzisionsstelle.

15. Vorrichtung nach Anspruch 11, die zum Reparieren eines Skelettgelenkdefektes in einem Säugetier geeignet ist, worin:

- a) die Matrix mehrere verschiedene Reste von einem proximalen oder distalen Halbgelenk umfasst, einschließlich mindestens eines nicht mineralisierten Gelenkgewebes; und
- b) das osteogene Protein auf der Oberfläche der genannten Matrix vorliegt, daran adsorbiert oder darauf präzipitiert ist.

16. Verwendung der Matrix und des osteogenen Proteins nach Anspruch 15 zur Herstellung einer Vorrichtung nach Anspruch 15 zum Reparieren eines Skelettgelenkdefektes in einem Säugetier.

17. Verwendung der Matrix und des osteogenen Proteins nach Anspruch 15 zur Herstellung einer Vorrichtung nach Anspruch 15 zur *in vivo*-Bildung eines funktionellen Ersatzskelettgelenks in einem Säugetier.

18. Verwendung der Matrix und des osteogenen Proteins nach Anspruch 15 zur Herstellung einer Vorrichtung nach Anspruch 15 zur Verwendung in einem Verfahren zum Induzieren einer *in vivo*-Bildung eines Ersatzskelettgelenks in einem Säugetier, wobei das Verfahren umfasst, Implantieren der Vorrichtung in einen Ort eines Säugetiers, um die Bildung eines funktionellen Ersatzskelettgelenks zu induzieren, das mehrere verschiedene Gewebe darin umfasst.

19. Vorrichtung nach Anspruch 1, die dafür geeignet ist, ein stabiles, funktionelles, vitalisiertes artikulierendes Skelettgelenk an einer defekten Stelle eines Säugetiers zu bilden, worin:

- a) die Matrix von einem Säugetierspenderskelettgelenk exzidiert wird;
- b) die Matrix Abmessungen und eine Form aufweist, die denen/der des Skelettgelenks ähnlich sind/ist, und Reste umfasst, die so bemessen sind, dass sie bezüglich Form und Strukturbeziehung den zu ersetzenden mehreren verschiedenen Geweben entsprechen; und
- c) das osteogene Protein in einer Menge vorliegt, die ausreicht, um die Bildung einer vitalisierten artikulierenden Oberfläche und von vitalisierten mehreren verschiedenen Geweben zu induzieren, so dass die Regeneration eines stabilen, funktionellen, vitalisierten artikulierenden Skelettgelenks an der defekten Stelle ermöglicht wird.

20. Verwendung der Matrix und des osteogenen Proteins nach Anspruch 19 zur Herstellung einer Vorrichtung nach Anspruch 19 zum Reparieren eines Skelettgelenkdefekts in einem Säugetier.

21. Verwendung der Matrix und des osteogenen Proteins nach Anspruch 19 zur Herstellung einer Vorrichtung nach Anspruch 19 zur Wiederherstellung eines stabilen, funktionellen, vitalisierten artikulierenden Skelettgelenks an einer Gelenkdefektstelle in einem Säugetier.

22. Verwendung der Matrix und des osteogenen Proteins nach Anspruch 19 zur Herstellung einer Vorrichtung nach Anspruch 19 zur Verwendung in einem Verfahren zur Wiederherstellung eines stabilen, funktionellen, vitalisierten artikulierenden Skelettgelenks an einer Gelenkdefektstelle in einem Säugetier, wobei das Verfahren umfasst, Bereitstellen der Vorrichtung für die genannte Gelenkdefektstelle, um die Wiederherstellung eines stabilen, funktionellen, vitalisierten artikulierenden Skelettgelenks darin zu ermöglichen.
23. Vorrichtung nach Anspruch 19, die zur *in vivo*-Bildung mehrerer verschiedener, nicht mineralisierter Gewebe in einem stabilen, funktionellen, vitalisierten artikulierenden Skelettgelenk geeignet ist, worin die Reste eine Spezifität für mehrere verschiedene, nicht mineralisierende Gewebe haben oder davon abstammen, und das osteogene Protein in einer Menge vorliegt, die ausreicht, um die Bildung einer artikulierenden Oberfläche und mehrerer verschiedener nicht mineralisierter Gewebe zu induzieren, wodurch die Regeneration eines stabilen, funktionellen, vitalisierten artikulierenden Skelettgelenks an der genannten Defektstelle ermöglicht wird.
24. Verwendung der Matrix und des osteogenen Proteins nach Anspruch 23 zur Herstellung einer Vorrichtung nach Anspruch 23 zum Wiederherstellen mehrerer verschiedener nicht mineralisierter Gewebe in einem Skelettgelenk eines Säugetiers.
25. Verwendung der Matrix und des osteogenen Proteins nach Anspruch 23 für die Herstellung einer Vorrichtung nach Anspruch 23 zur Verwendung in einem Verfahren zur Wiederherstellung mehrerer verschiedener nicht mineralisierter Gewebe in einem Skelettgelenk eines Säugetiers, wobei das Verfahren umfasst, Bereitstellen der Vorrichtung an der Stelle des Gelenks, um die Wiederherstellung eines nicht mineralisierten Gewebes darin zu ermöglichen.
26. Verwendung nach Anspruch 25, wobei das wiederherzustellende, nicht mineralisierte Gewebe avaskuläres Gewebe umfasst.
27. Verwendung nach Anspruch 25, wobei das wiederherzustellende, nicht mineralisierte Gewebe ausgewählt ist unter Gelenkknorpel, Ligament, Tendo, Synovialkapsel, einer interagierenden Knochenanlagerungsstelle, einer Muskel-Knochen-Verbindungsstelle und Synovialmembrangewebe.
28. Verwendung nach einem der Ansprüche 5, 8 bis 10, 14, 18, 22 und 25 bis 27, wobei das wiederhergestellte oder ersetzte Skelettgelenk ein Synovialgelenk ist.
29. Verwendung nach einem der Ansprüche 5, 8 bis 10, 14, 15, 18, 22 und 25 bis 28, wobei das Verfahren ferner den Schritt umfasst, Implantierens eines Muskellappens in einen hohlen Abschnitt der Matrix der Vorrichtung.
30. Vorrichtung nach einem der Ansprüche 1, 2, 6, 11, 12, 15, 19 und 23 oder Verwendung nach einem der Ansprüche 3 bis 5, 7 bis 10, 13, 14, 16 bis 18, 20 bis 22 und 24 bis 29, wobei das osteogene Protein ausgewählt ist aus OP-1, OP-2, OPX, BMP2, BMP4, BMP5, BMP6, BMP9, einem Protein, umfassend die C-terminale-102 Aminosäuresequenz von DPP, Vgl, 60A, Vgr-1, oder einem natürlich vorkommenden oder biosynthetischen oder rekombinanten Derivat davon oder einem Homodimer oder Heterodimer von einem oder mehreren der genannten Proteine.
31. Vorrichtung oder Verwendung nach Anspruch 30, wobei das osteogene Protein OP-1 oder ein verwandtes osteogenes Protein oder ein Homodimer oder Heterodimer davon ist.
32. Vorrichtung oder Verwendung nach Anspruch 31, wobei das verwandte osteogene Protein ein Gerüst mit Sechs oder Sieben Cysteinen in der C-terminalen Region umfasst.
33. Vorrichtung oder Verwendung nach Anspruch 31, wobei das osteogene Protein OP-1 oder ein Homodimer oder Heterodimer davon ist.
34. Vorrichtung nach einem der Ansprüche 1, 2, 6, 11, 12, 15, 19, 23 und 30 bis 33 oder Verwendung nach einem der Ansprüche 3 bis 5, 7 bis 10, 13, 14, 16 bis 18, 20 bis 22, 24 bis 29 und 30 bis 33, wobei die Matrix durch Dehydrierung devitalisiert ist.
35. Vorrichtung oder Verwendung nach Anspruch 34, wobei die Matrix devitalisierte allogene oder xenogene Gewebe umfasst.
36. Vorrichtung nach einem der Ansprüche 1, 2, 6, 11, 12, 15, 19, 23 und 30 bis 35 oder Verwendung nach einem der

Ansprüche 3 bis 5, 7 bis 10, 13, 14, 16 bis 18, 20 bis 22, 24 bis 29 und 30 bis 36, wobei die Matrix Knochen und zugehörigen Gelenkknorpel umfasst, exzidiert von einem allogenen oder xenogenen Säugetierspenderskelettgelenk.

- 5 37. Vorrichtung oder Verwendung nach einem der Ansprüche 34 bis 36, wobei die Matrix devitalisiertes Gewebe von einem Säugetierspender umfasst.
38. Vorrichtung oder Verwendung nach einem der Ansprüche 34 bis 37, wobei die Matrix dehydratisiertes Säugetiergewebe umfasst.
- 10 39. Vorrichtung nach einem der Ansprüche 1, 2, 6, 11, 12, 15, 19, 23 und 30 bis 38 oder Verwendung nach einem der Ansprüche 3 bis 5, 7 bis 10, 13, 14, 16 bis 18, 20 bis 22, 24 bis 29 und 30 bis 38, wobei mindestens eines der mehreren verschiedenen Geweben (beispielsweise mindestens eines der nicht-mineralisierten Gewebe) ausgewählt ist unter Gelenkknorpel, Ligament, Tendo, Synovialkapsel, einer interagierenden Knochenanlagerungsstelle, einer Muskel-Knochen-Verbindungsstelle und Synovialmembrangewebe.
- 15 40. Vorrichtung oder Verwendung nach einem der Ansprüche 1 bis 38, wobei wenigstens eines der mehreren verschiedenen Gewebe (beispielsweise das nicht mineralisierte Gewebe) ein avaskuläres Gewebe ist.
- 20 41. Vorrichtung nach einem der Ansprüche 1, 2, 6, 11, 12, 15, 19, 23 und 30 bis 40 oder Verwendung nach einem der Ansprüche 3 bis 5, 7 bis 10, 13, 14, 16 bis 18, 20 bis 22, 24 bis 29 und 30 bis 40, wobei die mehreren verschiedenen Gewebe Knorpel (beispielsweise Gelenkknorpel) und Knochen umfassen.
- 25 42. Vorrichtung nach einem der Ansprüche 1, 2, 6, 11, 12, 15, 19, 23 und 30 bis 41 oder Verwendung nach einem der Ansprüche 3 bis 5, 7 bis 10, 13, 14, 16 bis 18, 20 bis 22, 24 bis 29 und 30 bis 41, wobei das Skelettgelenk ein Synovialgelenk oder artikulierendes Gelenk oder einen Teil des Synovialgelenks oder artikulierenden Gelenks definiert.
- 30 43. Vorrichtung oder Verwendung nach Anspruch 42, wobei das Skelettgelenk ein Synovialgelenk ist oder umfasst.
44. Vorrichtung nach einem der Ansprüche 1, 2, 6, 11, 12, 15, 19, 23 und 30 bis 43 oder Verwendung nach einem der Ansprüche 3 bis 5, 7 bis 10, 13, 14, 16 bis 18, 20 bis 22, 24 bis 29 und 30 bis 45, wobei die Vorrichtung ferner ein Material umfasst, ausgewählt unter Kollagen, Polymeren umfassend Monomere von Milchsäure, Glycolsäure, Buttersäure oder Kombinationen davon, Keramik wie Hydroxyapatit, Tricalciumphosphat oder Gemische davon.
- 35 45. Vorrichtung nach einem der Ansprüche 1, 2, 6, 11, 12, 15, 19, 23 und 30 bis 44 oder Verwendung nach einem der Ansprüche 3 bis 5, 7 bis 10, 13, 14, 16 bis 18, 20 bis 22, 24 bis 29 und 30 bis 44, wobei die Vorrichtung einen formbaren Feststoff umfasst oder weiter ein Material umfasst, das zur Bindung von teilchenförmiger Materie geeignet ist, um einen formbaren Feststoff zu bilden.
- 40 46. Verwendung nach Anspruch 13, wobei die Stelle einen zu ersetzenden endogenen Körperteil definiert.
47. Verwendung nach Anspruch 13, wobei die Matrix ferner Reste umfasst, die so bemessen sind, dass sie bezüglich Form und Strukturbeziehung mit den mehreren verschiedenen Geweben übereinstimmen.
- 45 48. Verwendung nach Anspruch 4 oder Anspruch 7, wobei die Matrix von allogenem oder xenogenem Gelenkknorpel abgeleitet ist.
49. Verwendung nach Anspruch 4 oder Anspruch 7, wobei die Vorrichtung einen formbaren Feststoff umfasst.
- 50 50. Verwendung nach Anspruch 4 oder Anspruch 7, wobei die Vorrichtung eine flexible Schicht umfasst.
51. Verwendung nach einem der Ansprüche 48 bis 50, wobei das osteogene Protein wie in Anspruch 30 definiert ist.
- 55 52. Vorrichtung nach einem der Ansprüche 1, 2, 6, 11, 12, 15, 19, 23 und 30 bis 47 zur Verwendung zum Implantieren in ein Säugetier.

Revendications

1. Dispositif approprié pour une implantation dans un mammifère, ledit dispositif comprenant :

- a) une matrice biocompatible et biorésorbable ou biodégradable définissant une structure unique qui permet d'y fixer des cellules infiltrantes, la matrice comprenant des résidus qui dérivent de plusieurs tissus distincts d'une articulation squelettique, au moins un desdits tissus étant un tissu non minéralisé ; et
- b) une protéine ostéogénique exogène disposée à la surface ou à l'intérieur de ladite matrice ;

dans lequel la matrice répartie d'une structure d'articulation squelettique dévitalisée.

2. Dispositif selon la revendication 1 approprié pour une implantation dans un mammifère pour remplacer un tissu non minéralisé in vivo dans une articulation squelettique, dans lequel :

- a) l'articulation squelettique est une hém articulation (par exemple une hém articulation proximale ou distale) et les tissus correspondent, quant à leur type, audit tissu faisant l'objet de la substitution ; et
- b) la fixation de cellules infiltrantes permet la régénération du tissu non minéralisé dans une articulation squelettique.

3. Utilisation de la matrice et de la protéine ostéogénique comme défini à la revendication 1 ou à la revendication 2 pour la fabrication d'un dispositif selon la revendication 1 ou selon la revendication 2 pour réparer une anomalie dans une articulation squelettique d'un mammifère.

4. Utilisation de la matrice et de la protéine ostéogénique comme défini à la revendication 1 ou à la revendication 2 pour la formation ou la restauration in vivo d'un tissu non minéralisé dans une articulation squelettique d'un mammifère.

5. Utilisation de la matrice et de la protéine ostéogénique comme défini à la revendication 1 ou à la revendication 2 dans un procédé pour réparer in vivo une anomalie de tissu non minéralisé dans une articulation squelettique d'un mammifère, ledit procédé comprenant le fait de procurer le dispositif à ladite anomalie de façon à y permettre la régénération dudit tissu non minéralisé.

6. Dispositif selon la revendication 1 ou 2, dans lequel le tissu non minéralisé est du cartilage articulaire.

7. Utilisation de la matrice et de la protéine ostéogénique comme défini à la revendication 1 pour la fabrication d'un dispositif selon la revendication 6 pour la formation in vivo de cartilage articulaire dans une articulation squelettique ou pour la préparation in vivo d'une anomalie dans le cartilage articulaire (par exemple à la surface d'un os) chez un mammifère (par exemple dans une cavité synoviale).

8. Utilisation de la matrice et de la protéine ostéogénique comme défini à la revendication 6 pour la fabrication d'un dispositif selon la revendication 3 à utiliser dans un procédé de formation in vivo d'un cartilage articulaire dans une articulation squelettique, ledit procédé comprenant l'implantation du dispositif à un site dans ledit mammifère de façon à y induire une formation de cartilage articulaire.

9. Utilisation de la matrice et de la protéine ostéogénique comme défini à la revendication 6 pour la fabrication d'un dispositif selon la revendication 3 à utiliser dans un procédé de réparation in vivo d'une anomalie de cartilage articulaire chez un mammifère (par exemple à la surface d'un os), ledit procédé comprenant l'implantation du dispositif dans le site de ladite anomalie de cartilage articulaire (par exemple en procurant le dispositif à la surface de l'os) afin d'y induire une formation de cartilage articulaire de substitution.

10. Utilisation selon la revendication 9, dans laquelle l'anomalie de cartilage articulaire se manifeste dans une cavité synoviale.

11. Dispositif selon la revendication 1, approprié pour faire office de matrice pour la formation in vivo d'une articulation squelettique fonctionnelle ou d'une partie de cette dernière, comprenant plusieurs tissus distincts, la protéine ostéogénique étant disposée à la surface de ladite matrice en une quantité suffisante pour induire une formation desdits plusieurs tissus distincts possédant des dimensions et des configurations qui épousent celles de l'articulation squelettique qui doit être réparée, pour permettre la régénération d'une articulation squelettique fonctionnelle.

12. Dispositif selon la revendication 1, approprié pour former une articulation squelettique de substitution, fonctionnelle, stable, qui comprend du cartilage articulaire et des tissus osseux à un site défectueux dans une articulation squelettique chez un mammifère, dans lequel :

a) la matrice est une matière de support excisée à partir de l'articulation squelettique d'un donneur mammalien, la matrice possédant des dimensions et des configurations qui imitent celles de l'articulation squelettique faisant l'objet de la substitution et comprenant des résidus de cartilage articulaire et d'os dont les dimensions correspondent, quant à leur configuration et à leur relation structurelle, auxdits plusieurs tissus distincts faisant l'objet de la substitution ; et

b) la protéine ostéogénique est disposée à la surface de ladite matrice en une quantité suffisante pour induire une formation d'os et de tissus cartilagineux articulaires associés, pour permettre la régénération d'une articulation squelettique fonctionnelle de remplacement au site défectueux.

13. Utilisation de la matrice et de la protéine ostéogénique, comme défini à la revendication 1, 11 ou 12 pour la fabrication d'un dispositif selon la revendication 1, 11 ou 12 dans le but de former une articulation squelettique stable, fonctionnelle, de substitution à un site défectueux dans une articulation squelettique chez un mammifère.

14. Utilisation de la matrice et de la protéine ostéogénique comme défini à la revendication 1, 11 ou 12 pour la fabrication d'un dispositif selon la revendication 1, 11 ou 12 à utiliser dans un procédé de substitution d'une articulation squelettique défectueuse, comprenant l'excision chirurgicale de ladite articulation squelettique défectueuse et l'implantation du dispositif au site de l'excision.

15. Dispositif selon la revendication 11, approprié pour réparer une anomalie dans une articulation squelettique chez un mammifère, dans lequel :

a) la matrice comprend plusieurs résidus distincts qui dérivent d'une hém articulation proximale ou distale englobant au moins un tissu non minéralisé d'une articulation ; et

b) la protéine ostéogénique est disposée sur la surface de ladite matrice ou bien est adsorbée ou encore précipitée sur ladite surface.

16. Utilisation de la matrice et de la protéine ostéogénique, comme défini à la revendication 15, pour la fabrication d'un dispositif selon la revendication 15 pour la réparation d'une anomalie dans une articulation squelettique chez un mammifère.

17. Utilisation de la matrice et de la protéine ostéogénique, comme défini à la revendication 15, pour la fabrication d'un dispositif selon la revendication 15 pour la formation in vivo d'une articulation squelettique fonctionnelle de substitution chez un mammifère.

18. Utilisation de la matrice et de la protéine ostéogénique, comme défini à la revendication 15, pour la fabrication d'un dispositif selon la revendication 15 à utiliser dans un procédé d'induction, dans un mammifère, de la formation in vivo d'une articulation squelettique de substitution, ledit procédé comprenant l'implantation du dispositif à un site dans un mammifère de façon à y induire la formation d'une articulation squelettique fonctionnelle de substitution comprenant plusieurs tissus distincts.

19. Dispositif selon la revendication 1, approprié pour former une articulation squelettique stable, fonctionnelle, innervée à un site défectueux chez un mammifère, dans lequel :

a) la matrice est excisée à partir d'une articulation squelettique provenant d'un donneur mammalien ;

b) la matrice possède des dimensions et une configuration qui imitent celles de l'articulation squelettique et comprend des résidus qui sont dimensionnés pour correspondre, quant à leur configuration et à leur relation structurelle, auxdits plusieurs tissus distincts faisant l'objet de la substitution ; et

c) la protéine ostéogénique est présente en une quantité suffisante pour induire la formation d'une surface d'articulation innervée et de plusieurs tissus distincts innervés pour permettre la régénération d'une articulation squelettique stable, fonctionnelle, innervée audit site défectueux.

20. Utilisation de la matrice et de la protéine ostéogénique, comme défini à la revendication 19, pour la fabrication d'un dispositif selon la revendication 19 pour la réparation d'une anomalie dans une articulation squelettique chez un

mammifère.

- 5 21. Utilisation de la matrice et de la protéine ostéogénique, comme défini à la revendication 19, pour la fabrication d'un dispositif selon la revendication 19 pour la restauration d'une articulation squelettique stable, fonctionnelle, innervée à un site d'articulation défectueux chez un mammifère.
- 10 22. Utilisation de la matrice et de la protéine ostéogénique, comme défini à la revendication 19, pour la fabrication d'un dispositif selon la revendication 19 pour la restauration d'une articulation squelettique stable, fonctionnelle, innervée à un site d'articulation défectueux chez un mammifère, ledit procédé comprenant le fait de procurer le dispositif audit site d'articulation pour y permettre la restauration d'une articulation squelettique stable, fonctionnelle, innervée.
- 15 23. Dispositif selon la revendication 19, approprié pour la formation in vivo de plusieurs tissus distincts non minéralisés dans une articulation squelettique stable, fonctionnelle, innervée, dans lequel lesdits résidus possèdent une spécificité pour plusieurs tissus distincts non minéralisés ou bien dérivent desdits plusieurs tissus, et la protéine ostéogénique est présente en une quantité suffisante pour induire la formation d'une surface d'articulation et de plusieurs tissus distincts non minéralisés en permettant la régénération d'une articulation stable, fonctionnelle, innervée audit site défectueux.
- 20 24. Utilisation de la matrice et de la protéine ostéogénique, comme défini à la revendication 23, pour la fabrication d'un dispositif selon la revendication 23 pour la restauration de plusieurs tissus distincts non minéralisés dans une articulation squelettique chez un mammifère.
- 25 25. Utilisation de la matrice et de la protéine ostéogénique, comme défini à la revendication 23, pour la fabrication d'un dispositif selon la revendication 23 dans un procédé pour la restauration de plusieurs tissus distincts non minéralisés dans une articulation squelettique chez un mammifère, ledit procédé comprenant le fait de procurer le dispositif au site de ladite articulation de façon à y permettre la restauration d'un tissu non minéralisé.
- 30 26. Utilisation selon la revendication 25, dans laquelle le tissu non minéralisé qui doit être restauré comprend un tissu avasculaire.
27. Utilisation selon la revendication 25, dans laquelle le tissu non minéralisé qui doit être restauré est choisi parmi le groupe comprenant un cartilage articulaire, un ligament, un tendon, une capsule synoviale, un site d'attachement osseux interdépendant, un site d'articulation d'un muscle à un os et un tissu de membrane synoviale.
- 35 28. Utilisation selon l'une quelconque des revendications 5, 8 à 10, 14, 18, 22 et 25 à 27, dans laquelle l'articulation squelettique soumise à une restauration ou à une substitution est une articulation synoviale.
- 40 29. Utilisation selon l'une quelconque des revendications 5, 8 à 10, 14, 18, 22 et 25 à 28, dans laquelle le procédé comprend en outre l'étape consistant à implanter un lambeau musculaire dans une portion creuse de la matrice du dispositif.
- 45 30. Dispositif selon l'une quelconque des revendications 1, 2, 6, 11, 12, 15, 19 et 23 ou utilisation selon l'une quelconque des revendications 3 à 5, 7 à 10, 13, 14, 16 à 18, 20 à 22 et 24 à 29, dans lequel ou dans laquelle la protéine ostéogénique est choisie parmi le groupe comprenant OP-1, OP-2, OPX, BMP2, BMP4, BMP5, BMP6, BMP9, une protéine comprenant, à son extrémité C-terminale, la séquence comportant 102 acides aminés de DPP, Vg1, 60A, Vgr-1 ou un de ses dérivés provenant d'une source naturelle ou d'une biosynthèse ou de type recombinant ou encore un homodimère ou un hétérodimère de l'une quelconque desdites une ou plusieurs protéines.
- 50 31. Dispositif ou utilisation selon la revendication 30, dans lequel ou dans laquelle la protéine ostéogénique est OP-1 ou une protéine ostéogénique apparentée ou encore un de ses homodimères ou de ses hétérodimères.
32. Dispositif ou utilisation selon la revendication 31, dans lequel ou dans laquelle la protéine ostéogénique apparentée comprend un squelette de six ou sept résidus cystéine dans la région C-terminale.
- 55 33. Dispositif ou utilisation selon la revendication 31, dans lequel ou dans laquelle la protéine ostéogénique est OP-1 ou bien un de ses homodimères ou de ses hétérodimères.
34. Dispositif selon l'une quelconque des revendications 1, 2, 6, 11, 12, 15, 19, 23 et 30 à 33 ou utilisation selon l'une

quelconque des revendications 3 à 5, 7 à 10, 13, 14, 16 à 18, 20 à 22, 24 à 29 et 30 à 33, dans lequel ou dans laquelle la matrice est dévitalisée par déshydratation.

- 5 35. Dispositif ou utilisation selon la revendication 34, dans lequel ou dans laquelle la matrice comprend des tissus allogéniques ou xénogéniques dévitalisés.
- 10 36. Dispositif selon l'une quelconque des revendications 1, 2, 6, 11, 12, 15, 19, 23 et 30 à 35 ou utilisation selon l'une quelconque des revendications 3 à 5, 7 à 10, 13, 14, 16 à 18, 20 à 22, 24 à 29 et 30 à 35, dans lequel ou dans laquelle la matrice comprend de l'os et du cartilage articulaire associé, excisés à partir de l'articulation squelettique d'un donneur mammalien allogénique ou xénogénique.
- 15 37. Dispositif ou utilisation selon l'une quelconque des revendications 34 à 36, dans lequel ou dans laquelle la matrice comprend un tissu dévitalisé provenant d'un donneur mammalien.
- 20 38. Dispositif ou utilisation selon l'une quelconque des revendications 34 à 37, dans lequel ou dans laquelle la matrice comprend un tissu mammalien déshydraté.
- 25 39. Dispositif selon l'une quelconque des revendications 1, 2, 6, 11, 12, 15, 19, 23 et 30 à 38 ou utilisation selon l'une quelconque des revendications 3 à 5, 7 à 10, 13, 14, 16 à 18, 20 à 22, 24 à 29 et 30 à 38, dans lequel ou dans laquelle au moins un desdits plusieurs tissus distincts (par exemple au moins un desdits tissus non minéralisés) est choisi parmi le groupe comprenant un cartilage articulaire, un ligament, un tendon, une capsule synoviale, un site d'attachement osseux interdépendant, un site d'articulation d'un muscle à un os et un tissu de membrane synoviale.
- 30 40. Dispositif ou utilisation selon l'une quelconque des revendications 1 à 38, dans lequel ou dans laquelle au moins un desdits plusieurs tissus distincts (par exemple le tissu non minéralisé) est un tissu avasculaire.
- 35 41. Dispositif selon l'une quelconque des revendications 1, 2, 6, 11, 12, 15, 19, 23 et 30 à 40 ou utilisation selon l'une quelconque des revendications 3 à 5, 7 à 10, 13, 14, 16 à 18, 20 à 22, 24 à 29 et 30 à 40, dans lequel ou dans laquelle lesdits plusieurs tissus distincts comprennent du cartilage (par exemple du cartilage articulaire) et de l'os.
- 40 42. Dispositif selon l'une quelconque des revendications 1, 2, 6, 11, 12, 15, 19, 23 et 30 à 41 ou utilisation selon l'une quelconque des revendications 3 à 5, 7 à 10, 13, 14, 16 à 18, 20 à 22, 24 à 29 et 30 à 41, dans lequel ou dans laquelle l'articulation squelettique définit une articulation proprement dite ou une articulation synoviale ou encore une portion de ladite articulation proprement dite ou de ladite articulation synoviale.
- 45 43. Dispositif ou utilisation selon la revendication 42, dans lequel ou dans laquelle l'articulation squelettique comprend une articulation synoviale ou est une telle articulation.
- 50 44. Dispositif selon l'une quelconque des revendications 1, 2, 6, 11, 12, 15, 19, 23 et 30 à 43 ou utilisation selon l'une quelconque des revendications 3 à 5, 7 à 10, 13, 14, 16 à 18, 20 à 22, 24 à 29 et 30 à 43, dans lequel ou dans laquelle le dispositif comprend en outre une matière choisie parmi le groupe comprenant du collagène, des polymères comprenant des monomères d'acide lactique, d'acide glycolique, d'acide butyrique ou de leurs combinaisons, des matières céramiques telles que l'hydroxylapatite, du phosphate tricalcique ou encore leurs mélanges.
- 55 45. Dispositif selon l'une quelconque des revendications 1, 2, 6, 11, 12, 15, 19, 23 et 30 à 44 ou utilisation selon l'une quelconque des revendications 3 à 5, 7 à 10, 13, 14, 16 à 18, 20 à 22, 24 à 29 et 30 à 44, dans lequel ou dans laquelle le dispositif comprend un produit solide apte à être moulé ou comprend en outre une matière appropriée pour la liaison d'une matière particulaire pour obtenir un produit solide apte à être moulé.
46. Utilisation selon la revendication 13, dans laquelle le site définit une partie du corps endogène qui doit faire l'objet d'une substitution.
47. Utilisation selon la revendication 13, dans laquelle la matrice comprend en outre des résidus qui sont dimensionnés pour correspondre, quant à leur configuration et quant à leur relation structurelle, auxdits plusieurs tissus distincts.
48. Utilisation selon la revendication 4 ou 7, dans laquelle la matrice dérive d'un cartilage articulaire allogénique ou xénogénique.

EP 0 762 903 B2

49. Utilisation selon la revendication 4 ou 7, dans laquelle le dispositif comprend un produit solide apte à être moulé.

50. Utilisation selon la revendication 4 ou 7, dans laquelle le dispositif comprend une feuille flexible.

5 51. Utilisation selon l'une quelconque des revendications 48 à 50, dans laquelle la protéine ostéogénique est telle que définie à la revendication 30.

52. Dispositif selon l'une quelconque des revendications 1, 2, 6, 11, 12, 15, 19, 23 et 30 à 45 à utiliser lors d'une implantation dans un mammifère.

10

15

20

25

30

35

40

45

50

55

morphology and by its biochemistry. Morphologically, articular cartilage is characterized by superficial versus mid versus deep "zones" which show a characteristic gradation of features from the surface of the tissue to the base of the tissue adjacent to the bone. In the superficial zone, for example, chondrocytes are flattened and lie parallel to the surface embedded in an extracellular network that contains tangentially arranged collagen and few proteoglycans. In the mid zone, chondrocytes are spherical and surrounded by an extracellular network rich in proteoglycans and obliquely organized collagen fibers. In the deep zone, close to the bone, the collagen fibers are vertically oriented. The keratan sulphate rich proteoglycans increase in concentration with increasing distance from the cartilage surface. For a detailed description of articular cartilage micro-structure, see, for example, (Aydelotte and Kuettner. (1988), Conn. Tiss. Res. 18:205; Zanetti et al., (1985), J. Cell Biol. 101:53; and Poole et al., (1984), J. Anat. 138:13.

[0010] Biochemically, articular collagen can be identified by the presence of Type II and Type IX collagen, as well as by the presence of well-characterized proteoglycans, and by the absence of Type X collagen, which is associated with endochondral bone formation.

[0011] In normal articular cartilage, a balance exists between synthesis and destruction of the above-described extracellular network. However, in tissue subjected to repeated trauma, for example due to friction between misaligned bones in contact with one another, or in joint diseases characterized by net loss of articular cartilage, e.g., osteoarthritis, an imbalance occurs between synthesis and degradation.

[0012] Two types of defects are recognized in articular surfaces, i.e., full-thickness defects and superficial defects. These defects differ not only in the extent of physical damage to the cartilage, but also in the nature of the repair response each type of lesion can elicit.

[0013] Full-thickness defects of an articulating surface include damage to the hyaline cartilage, the calcified cartilage layer and the subchondral bone tissue with its blood vessels and bone marrow. Full-thickness defects can cause severe pain since the bone plate contains sensory nerve endings. Such defects generally arise from severe trauma and/or during the late stages of degenerative joint disease, such as osteoarthritis. Full-thickness defects may, on occasion, lead to bleeding and the induction of a repair reaction from the subchondral bone. In such instances, however, the repair tissue formed is a vascularized fibrous type of cartilage with insufficient biomechanical properties, and does not persist on a long-term basis.

[0014] In contrast, superficial defects in the articular cartilage tissue are restricted to the cartilage tissue itself. Such defects are notorious because they do not heal and show no propensity for repair reactions. Superficial defects may appear as fissures, divots, or clefts in the surface of the cartilage, or they may have a "crab-meat" appearance in the affected tissue. They contain no bleeding vessels (blood spots) such as are seen in full-thickness defects. Superficial defects may have no known cause, however, they are often the result of mechanical derangements which lead to a wearing down of the cartilaginous tissue. Such mechanical derangements may be caused by trauma to the joint, e.g., a displacement of torn meniscus tissue into the joint, meniscectomy, a laxation of the joint by a torn ligament, malalignment of joints, or bone fracture, or by hereditary diseases. Superficial defects are also characteristic of early stages of degenerative joint diseases, such as osteoarthritis. Since the cartilage tissue is not innervated or vascularized, superficial defects do not heal and often degenerate into full-thickness defects.

[0015] Replacement with prosthetic joints is currently the preferred option for serious degeneration of joint function involving loss of articular cartilage. It is anticipated that a means for functional reconstruction of joint complexes, including regeneration and repair of articular cartilage, will have a profound effect on alloplastic joint replacement surgery and the management of degenerative joint disease.

[0016] Like articular cartilage, joint ligaments which serve to connect interacting bones in the joint, have little or no self regenerative propensities. Ligaments typically are composed of substantially parallel bundles of white fibrous tissue. They are pliant and flexible to allow substantially complete freedom of movement, but are inextensible to prevent over-extension of the interacting bones in the joint. Like cartilage, ligament tissue is substantially devoid of blood vessels and has little or no self-regenerative properties. Surgical repair of torn or damaged ligament tissue to date is limited to use of autogenous grafts or synthetic materials that are surgically attached to the articular extremities of the bones. Allogenic ligaments typically fail mechanically, presumably due to the treatments required to render these materials biocompatible. Similarly, tendons are rope-like structures which connect muscle fibers to bone or cartilage and which are formed from substantially parallel fibroids of white connective tissue. The synovial capsule is composed of a thin layer of ligamentous tissue which encloses the joint and allows the joint to be bathed in the lubricating synovial fluid. The interior of the joint capsule is lined with a thin membrane of connective tissue having branched connective-tissue corpuscles defining the synovial membrane, and which is primarily responsible for secreting synovial fluid into the cavity. The integrity of this membrane therefore, is important to maintaining a source for the lubricating synovial fluid. Repair of these tissues in orthopedic contexts typically is limited to resuturing of existing tissue.

[0017] Bone tissue differs significantly from the other tissues described hereinabove, including cartilage tissue. Specifically, bone tissue is vascularized tissue composed both of cells and a biphasic medium which is composed of a mineralized, inorganic component (primarily hydroxyapatite crystals) and an organic component comprised primarily of Type I collagen. Glycosaminoglycans constitute less than 2% of this organic component and less than 1% of the biphasic